Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Otorhinolaryngology

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 631 articles:
HTML format



Single Articles


    November 2026
  1. MUTHURAJ Y, Clementswami S
    Comment on "Effects of exercise on health-related fitness and patient-reported outcomes in survivors of head and neck cancer: a systematic review and meta-analysis".
    Oral Oncol. 2026;183:108183.
    PubMed    


  2. LI M
    Considerations on osteosarcopenia as a prognostic factor in head and neck cancer surgery.
    Oral Oncol. 2026;183:108203.
    PubMed    


  3. HU W, Zhou L, Yang X
    Comment on "Differential associations between treatment delay and survival across head and neck cancer subsites: a national hospital-based framework for risk-stratified prioritization".
    Oral Oncol. 2026;183:108199.
    PubMed    


    October 2026
  4. XIE Y, Lin Y, He J, Ji Y, et al
    Mechanism study on CSF3-Induced M2 polarization of tumor-associated macrophages and CCL9 secretion in promoting tumor progression in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;183:108176.
    PubMed     Abstract available


  5. ROUSSEL LM, Berghian A, Hapdey S, Clatot F, et al
    The 5-mm margin in head and neck cancer surgery: From uncontrolled historical dogma to personalised surgery.
    Oral Oncol. 2026;182:108194.
    PubMed     Abstract available


  6. NEH H, MacRae DC, de Vette SPM, van der Hoek L, et al
    Predicting taste alteration in head and neck cancer patients using 3D transformer-based deep learning model.
    Oral Oncol. 2026;182:108192.
    PubMed     Abstract available


  7. KARPAGAVALLI G, Prakash IA, Ariyalakshmi B, Regina PF, et al
    Comment on "Does discharge location following head and neck cancer surgery affect quality outcomes?".
    Oral Oncol. 2026;182:108182.
    PubMed    


  8. LONG CQ
    Does osteosarcopenia add prognostic information beyond osteopenia alone in head and neck cancer?
    Oral Oncol. 2026;182:108190.
    PubMed    


  9. GUPTA K, Popat S, Sarin D
    Oncological and quality-of-life outcomes after robotic versus open neck dissection in oral cavity cancer: a prospective matched-pair analysis.
    Oral Oncol. 2026;182:108185.
    PubMed     Abstract available


  10. LI SH
    Does nodal burden Truly Modify the prognostic effect of extranodal extension in oral Cancer?
    Oral Oncol. 2026;182:108177.
    PubMed    


  11. YE T
    Separating rurality from population composition and subsite coding in head and neck cancer mortality trends.
    Oral Oncol. 2026;182:108179.
    PubMed    


  12. LECHIEN JR, Vaira LA, Baudouin R, Guarino P, et al
    Transoral robotic versus laser surgery for cT1-T3 supraglottic laryngeal cancers: a systematic review and meta-analysis of comparative and non-comparative studies.
    Oral Oncol. 2026;182:108172.
    PubMed     Abstract available


  13. SUZUKI K, Ueki Y, Ohno Y, Ohshima S, et al
    Prognostic significance and predictors of pathological response following neoadjuvant paclitaxel, carboplatin, and cetuximab therapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;182:108175.
    PubMed     Abstract available


  14. SASAKI AT, Boe LA, Eagan A, Patel SG, et al
    Differential associations between treatment delay and survival across head and neck cancer subsites: a national hospital-based framework for risk-stratified prioritization.
    Oral Oncol. 2026;182:108168.
    PubMed     Abstract available


  15. SANABRIA A, Simo R, Cohen O, Kowalski LP, et al
    Neoadjuvant treatment or chemoselection in head and neck carcinoma. What makes one term different from another.
    Oral Oncol. 2026;182:108167.
    PubMed    


  16. WU L, He J, Zhou Z, Luo R, et al
    Concurrent Versus Sequential PD-1 Blockade With Locoregional Radiotherapy After Chemoimmunotherapy in De Novo Metastatic Nasopharyngeal Carcinoma: A Landmark Analysis.
    Oral Oncol. 2026;182:108164.
    PubMed     Abstract available


  17. ALI S, Mohammed MES, Yousif M, Alabdalhussein A, et al
    Incidence of retropharyngeal lymph node involvement in oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis.
    Oral Oncol. 2026;181:108090.
    PubMed     Abstract available


  18. YANAN D, Zhao T, Chuanliang S, Junzheng W, et al
    Comments on: prognostic value of the 5-Item Modified Frailty Index in elderly patients undergoing free flap reconstruction for head and neck cancer.
    Oral Oncol. 2026;182:108154.
    PubMed    


    September 2026
  19. LONG CQ
    Interpreting distant metastasis risk in MRI-Defined N3 nasopharyngeal carcinoma in the presence of competing events.
    Oral Oncol. 2026;182:108160.
    PubMed    


  20. SMITH JD, Santiago R, Doerfler R, Harris MK, et al
    The impact of regional lymph node depletion on response to anti-PD-1 therapy in recurrent and metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2026;182:108155.
    PubMed     Abstract available


  21. URAGUCHI K, Rikitake R, Tsumura M, Ando M, et al
    Board-certified facilities and survival in head and neck cancer in Japan: A hospital-based cancer registry study.
    Oral Oncol. 2026;182:108152.
    PubMed     Abstract available


  22. PATEL AN, Wu SS, Colevas AD, Divi V, et al
    Estimated costs of intravenous vs subcutaneous pembrolizumab in perioperative head and neck cancer: subcutaneous administration is unlikely to reduce costs.
    Oral Oncol. 2026;182:108125.
    PubMed    


  23. CHEN F, Yang X
    Letter to the Editor: Exercise prehabilitation in head and neck cancer patients proposed for definitive chemoradiotherapy: The FIT4TREAT randomized controlled trial.
    Oral Oncol. 2026;182:108144.
    PubMed    


  24. HONGO T, Watanuki Y, Hirano Y, Yamauchi M, et al
    Prognostic impact of osteosarcopenia in patients with head and neck cancer undergoing radical resection and reconstructive surgery.
    Oral Oncol. 2026;182:108141.
    PubMed     Abstract available


  25. WANG Y, You K, Lan X, Liang P, et al
    Pretreatment MRI-defined necrotic nodal phenotypes identify distant metastasis risk heterogeneity in N3 nasopharyngeal carcinoma.
    Oral Oncol. 2026;182:108135.
    PubMed     Abstract available


  26. HONG MH, Lee S, Kim CG, Son W, et al
    Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745].
    Oral Oncol. 2026 Sep 4:108114. doi: 10.1016/j.oraloncology.2026.108114.
    PubMed    


  27. OKUYAMA K, Yanamoto S
    Integrating minimal residual disease into postoperative treatment selection for head and neck cancer.
    Oral Oncol. 2026;182:108121.
    PubMed     Abstract available


  28. KHADERI IM, Kandahari N, Saleh AW, Hackman TG, et al
    Development of the TORS severe outcome score: a preoperative risk stratification tool for postoperative morbidity in oropharyngeal cancer.
    Oral Oncol. 2026;180:108058.
    PubMed     Abstract available


  29. THARIAT J, Marcy PY, Preudhomme R, Gadan C, et al
    Postoperative radiotherapy delineation after mandibular bone flap reconstruction in oral cavity and oropharyngeal cancers.
    Oral Oncol. 2026;180:108054.
    PubMed     Abstract available


  30. ZADIK Y, Gavish L, Hanut A, Finfter O, et al
    High-power laser photobiomodulation therapy for immediate relief of mucositis-related odynophagia.
    Oral Oncol. 2026;180:108049.
    PubMed     Abstract available


  31. STROJAN P, Zagar T, Sifrer R, Didanovic V, et al
    Primary treatment modalities and p16 status in oropharyngeal squamous cell carcinoma outcomes: a tertiary center study with propensity score analysis.
    Oral Oncol. 2026;180:108039.
    PubMed     Abstract available


    August 2026
  32. GARCIA C, Leao I, Pinto D, Rato ND, et al
    Exercise prehabilitation in head and neck cancer patients proposed for definitive chemoradiotherapy: The FIT4TREAT randomized controlled trial.
    Oral Oncol. 2026;181:108119.
    PubMed     Abstract available


  33. FILIPPINI DM, Carosi F, Tomaciello M, Monte A, et al
    HPV circulating tumor DNA as a potential prognostic and predictive biomarker in head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2026;181:108116.
    PubMed     Abstract available


  34. BRADSHAW J, Tardif J, Lott DG, Ramaswamy AT, et al
    Radiation-associated dysphagia in head and neck cancer: A narrative review of surgical management, diagnosis, and emerging directions.
    Oral Oncol. 2026;181:108118.
    PubMed     Abstract available


  35. CLATOT F, Vozy A, Dominiak G, Luciani L, et al
    Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study).
    Oral Oncol. 2026;181:108106.
    PubMed     Abstract available


  36. LI L, Wang Z, Qin Z, Cai Z, et al
    Association of glycaemic control with post-radiation nasopharyngeal necrosis in diabetic patients with nasopharyngeal carcinoma.
    Oral Oncol. 2026;181:108112.
    PubMed     Abstract available


  37. THOMAS EA, Liu J, Yu M, Heft Neal ME, et al
    Rural-Urban disparities in head and neck cancer mortality in the United States: Subsite-Specific Trends, 2010-2024.
    Oral Oncol. 2026;181:108111.
    PubMed    


  38. DALMEIJER SWR, Baidun AS, Sjogren EV, Dronkers EAC, et al
    Positive Margin Rate Following Transoral Surgery in T2-T3 Laryngeal Carcinoma - a Systematic Review and Meta-Analysis.
    Oral Oncol. 2026;181:108113.
    PubMed     Abstract available


  39. SOBHANI S
    Promise and pitfalls of structure-based classification of radiologic extranodal extension in nasopharyngeal carcinoma.
    Oral Oncol. 2026;181:108109.
    PubMed    


  40. MATSUDA Y, Fujioka-Kobayashi M, Tatsumi H, Sonoyama-Osako R, et al
    Exploratory estimation of minimal clinically important deterioration in oral and swallowing function after oral cancer treatment: A prospective observational study.
    Oral Oncol. 2026;181:108108.
    PubMed     Abstract available


  41. DIETZE A, Zabini A, Schanne DH, Elicin O, et al
    De-escalation of radiotherapy in HPV-negative non-nasopharyngeal head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2026;181:108095.
    PubMed     Abstract available


  42. WU H
    Caution is warranted before omitting neck dissection after neoadjuvant chemoimmunotherapy in cT3-4N0M0 oral squamous cell carcinoma.
    Oral Oncol. 2026;181:108105.
    PubMed    


  43. LIU R, Wang Z, Yang X, He J, et al
    Health-Related quality of life (HRQoL) and health state utility values (HSUV) in patients with head and neck Cancer: A systematic review and Meta-Analysis.
    Oral Oncol. 2026;181:108097.
    PubMed     Abstract available


  44. TOPKAN E, Selek U
    Comment on Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2026;181:108096.
    PubMed    


  45. SUDARSON J
    Commentary on "Risk-benefit stratification for immune checkpoint inhibitor therapy in head and neck cancer based on immune-related adverse events and treatment discontinuation using routine clinical indicators beyond PD-L1 expression".
    Oral Oncol. 2026;181:108099.
    PubMed     Abstract available


  46. NAGAOKA M, Omura K, Fukuzato S, Ishida K, et al
    Early oncologic outcomes of endoscope-assisted total maxillectomy for maxillary sinus squamous cell carcinoma: A comparative study with conventional surgery.
    Oral Oncol. 2026;179:108023.
    PubMed     Abstract available


  47. OHKOSHI A, Katagiri K, Kano S, Yagi K, et al
    Treatment and prognosis of subglottic cancers: a 10-year, multicenter, retrospective study in northern Japan.
    Oral Oncol. 2026;179:108021.
    PubMed     Abstract available


  48. BROWN MH, Mendes WS, Song Y, Shetty AC, et al
    High frequency of RB1 mutations p16 positive early stage oropharyngeal carcinoma: A genomic and transcriptomic analysis.
    Oral Oncol. 2026;179:108002.
    PubMed     Abstract available


    July 2026
  49. TALOR E, Lavin P, Cipriano J, Markovic D, et al
    A novel neoadjuvant immunotherapy confers improved overall survival in oral cancer patients with low tumor PD-L1 expression The IT-MATTERS Clinical trial - Prognostic role of tumor PD-L1 expression.
    Oral Oncol. 2026;181:108092.
    PubMed     Abstract available


  50. SYKES J, Uribe Sanchez ED, Benito D, Danyluk A, et al
    Prognostic value of the 5-Item Modified Frailty Index in elderly patients undergoing free flap reconstruction for head and neck cancer.
    Oral Oncol. 2026;181:108088.
    PubMed     Abstract available


  51. GIUDICI F, Polesel J, Tagliabue M, Fratta E, et al
    Evolution of hazard of recurrence and death after surgery for oropharyngeal cancer according to HPV status.
    Oral Oncol. 2026;181:108079.
    PubMed     Abstract available


  52. TOPKAN E, Selek U
    Comment on "Elective neck dissection and adjuvant therapy in N0 major salivary gland cancer: an analysis of the SEER cancer database".
    Oral Oncol. 2026;181:108091.
    PubMed    


  53. GARCIA-AGULLO J, Santos V, Garcia-Mayea Y, de Luxan-Delgado B, et al
    NGFR expression predicts tumor recurrence in radiotherapy/chemoradiotherapy-treated HPV-negative pharyngeal squamous cell carcinoma.
    Oral Oncol. 2026;180:108080.
    PubMed     Abstract available


  54. SHARMAN MOSER S, Ziv D, Hoshen M, Gazit S, et al
    REVEAL study - real-world database analysis of patients with locally advanced head and neck squamous cell carcinoma in Israel.
    Oral Oncol. 2026;180:108077.
    PubMed     Abstract available


  55. ZHU B, Wen Z, Chen K, Zhu L, et al
    Pretreatment multiparametric MRI-based habitat radiomics and 2.5D deep learning for predicting early complete response to induction chemoimmunotherapy in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2026;180:108072.
    PubMed     Abstract available


  56. FANG Q, Cao F, Zhao Z, Lin R, et al
    omitting neck dissection in cT3-4N0M0 oral squamous cell carcinoma with Imaging-Negative nodes after neoadjuvant chemoimmunotherapy: A retrospective cohort study.
    Oral Oncol. 2026;180:108076.
    PubMed     Abstract available


  57. YAMIN T, Bergman D, Bartal K, Tiomkin E, et al
    The gender gap in HPV Literacy: A Cross-Sectional study of patient awareness of HPV-Related oropharyngeal carcinoma in men in the vaccine era.
    Oral Oncol. 2026;180:108075.
    PubMed     Abstract available


  58. HAM ND, Ershadifar S, Garber B, Li M, et al
    Patient preferences for mental health care in head and neck cancer: A head and neck cancer Alliance survey.
    Oral Oncol. 2026;180:108074.
    PubMed     Abstract available


  59. GAFFNEY J, France A, Rieu R, Wang Y, et al
    Evaluation of radiotherapy dose and survival outcomes for teenagers, and young adults with nasopharyngeal carcinoma in UK & Ireland.
    Oral Oncol. 2026;180:108062.
    PubMed     Abstract available


  60. KABONGO CM, Bowman T, Tracy J, Soneru C, et al
    Changing epidemiology of sinonasal cancer in the United States.
    Oral Oncol. 2026;178:107996.
    PubMed     Abstract available


    June 2026
  61. TOPKAN E, Somay E, Selek U
    Re: Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.
    Oral Oncol. 2026;180:108067.
    PubMed    


  62. OU C, Qi L, Lai H, Ye J, et al
    Mechanisms and clinical challenges of ICB-mediated remodeling of the tumor microenvironment in nasopharyngeal carcinoma.
    Oral Oncol. 2026;180:108017.
    PubMed     Abstract available


  63. LYU Y, Chen L, Cen X, Deng Y, et al
    The survival benefit of postoperative radiotherapy in pN1 head and neck squamous cell carcinoma without adverse pathological features: analysis of the SEER database.
    Oral Oncol. 2026;180:108055.
    PubMed     Abstract available


  64. HONG MH, Lee S, Kim CG, Son W, et al
    Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745].
    Oral Oncol. 2026 Jun 20:108052. doi: 10.1016/j.oraloncology.2026.108052.
    PubMed    


  65. TOPKAN E, Selek U
    Evaluation of a quasi-automatic treatment planning workflow for head-and-neck cancer in radiotherapy.
    Oral Oncol. 2026;180:108059.
    PubMed    


  66. TAPESCU I, Brody RM, Cao AC, Le K, et al
    Predictors and outcomes of pathologic retropharyngeal lymph nodes in HPV-related oropharyngeal cancer.
    Oral Oncol. 2026;180:108056.
    PubMed     Abstract available


  67. LIU J, Fan Y, He C, Jin T, et al
    Structure-specific involvement in advanced cervical lymph node extranodal extension predicts prognosis in nasopharyngeal carcinoma: A multi-center study.
    Oral Oncol. 2026;180:108050.
    PubMed     Abstract available


  68. XUE L, Zhou J, Tang W, Zhao W, et al
    Intravenous amivantamab after cetuximab failure in recurrent or metastatic head and neck squamous cell carcinoma: a single-centre retrospective real-world cohort study.
    Oral Oncol. 2026;180:108051.
    PubMed     Abstract available


  69. BOLDES T, Oanunu U, Machnes O, Dudkiewicz D, et al
    Efficacy of cetuximab-based regimens after immune checkpoint inhibitor failure in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Oral Oncol. 2026;180:108041.
    PubMed     Abstract available


  70. JIA B, He M, Ren J, Li G, et al
    Development and internal validation of an explainable machine learning model for predicting textbook outcome after free flap reconstruction in oral cancer.
    Oral Oncol. 2026;179:108037.
    PubMed     Abstract available


  71. NIJJAR YS, Sapir E, Corn BW, Gensheimer MF, et al
    Evaluation of the ESMO-magnitude of clinical benefit scale version 2.0 for the definitive treatment of HPV positive oropharynx cancer with radiation therapy.
    Oral Oncol. 2026;179:108035.
    PubMed     Abstract available


    May 2026
  72. WILLIAMSON A, Burton S, Rajan Z, Kwong E, et al
    Salvage surgery for residual and recurrent head and neck squamous cell carcinoma (RESCUE): An IReC multicentre consecutive cohort study.
    Oral Oncol. 2026;179:107997.
    PubMed     Abstract available


  73. STAIBANO P, Au M, Ganly I, de Almeida JR, et al
    Elective neck dissection and adjuvant therapy in N0 major salivary gland cancer: An analysis of the SEER cancer database.
    Oral Oncol. 2026;179:108015.
    PubMed     Abstract available


  74. COSTANTINO A, Paleri V, Williamson A, Zhu J, et al
    Optimizing adjuvant therapy selection with machine learning after transoral surgery in HPV-related oropharyngeal cancer.
    Oral Oncol. 2026;179:108024.
    PubMed     Abstract available


  75. SCHAFER A, Zulch L, Steinsdorfer L, Donaubauer AJ, et al
    ATR inhibition in combination with hypofractionated radiotherapy is superior to ATM inhibition with regard to ex vivo CD8 + T cell activation particularly for HPV-negative head and neck cancer cells.
    Oral Oncol. 2026;179:108019.
    PubMed     Abstract available


  76. NEMADE H, Thaduri A, Gondi JT, Chava SK, et al
    Refining nodal classification in oral cancer: prognostic impact of nodal burden within N2b and implications for AJCC staging.
    Oral Oncol. 2026;179:108016.
    PubMed     Abstract available


  77. WANG L, Hu H
    Analytical validity and interpretive boundaries of circulating immunosenescence-related indicators in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;179:108008.
    PubMed    


  78. ZHOU Y, Chen C
    A thoughtful reflection on survival outcomes after sentinel lymph node biopsy versus elective neck dissection in early oral cancer.
    Oral Oncol. 2026;179:108011.
    PubMed    


  79. BAGCHI P, Baviskar P, Yennemadi S
    Considerations regarding functional suprahyoid neck dissection in early lower lip carcinoma.
    Oral Oncol. 2026;179:108013.
    PubMed    


  80. GAUDUCHON T, Digue L, Ferlay C, Treilleux I, et al
    Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.
    Oral Oncol. 2026;178:108004.
    PubMed     Abstract available


  81. LY S, Ruhle A, Bratman S, Cho J, et al
    Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2026;178:108006.
    PubMed     Abstract available


  82. ROOF SA, Sicard RM, Chennareddy S, Ahn S, et al
    Post-treatment circulating tumor DNA clinical features, prognosis in HPV-positive oropharynx cancer.
    Oral Oncol. 2026;178:108003.
    PubMed     Abstract available


  83. YILDIZ I, Tasci ES, Yucel S
    HPV-positive oropharyngeal squamous cell carcinoma: risk-adapted treatment strategies and biomarker-guided individualization.
    Oral Oncol. 2026;178:108005.
    PubMed     Abstract available


  84. GRIFFIN C, Donovan ML, Lawler C, Da Gama Duarte J, et al
    Tertiary lymphoid structures in head and neck squamous cell carcinoma as predictors of response to immunotherapy.
    Oral Oncol. 2026;178:107998.
    PubMed     Abstract available


  85. ZHANG Y, Lv P, Cao G, Qi N, et al
    A kinase-related gene signature predicts prognosis and therapeutic response in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;178:107981.
    PubMed     Abstract available


  86. ADIL AA, Smith JD, Almasri M, Lyden T, et al
    In-office secondary tracheoesophageal puncture with immediate voicing in post-laryngectomy patients.
    Oral Oncol. 2026;176:107951.
    PubMed     Abstract available


  87. LITTLE S, Williams MF, Gilkey M, Perez-Bello D, et al
    Veteran oropharyngeal cancer outcomes in the modern era: a multi-institutional retrospective analysis.
    Oral Oncol. 2026;176:107942.
    PubMed     Abstract available


  88. KIUCHI S, Matsuyama Y, Takeuchi K, Kusama T, et al
    Smoking, drinking, tooth loss and risk of oral-pharyngeal cancer mortality.
    Oral Oncol. 2026;176:107937.
    PubMed     Abstract available


  89. CHU F, Bandi F, Tagliabue M, Zorzi SF, et al
    Transoral laser microsurgery for glottic cancer: landmark 24-year single-institution experience with 661 patients and validation of the isoprognostic zone system.
    Oral Oncol. 2026;176:107917.
    PubMed     Abstract available


  90. WANG YT, Chu PY
    A single transoral laser microsurgery to simultaneously diagnose and treat early glottic cancer and premalignancies.
    Oral Oncol. 2026;176:107920.
    PubMed     Abstract available


  91. NAGENDRABALAN N, Sahovaler A, Payne K, Shamat HA, et al
    Survival in node-positive early oral squamous cell carcinoma following sentinel lymph node biopsy or elective neck dissection.
    Oral Oncol. 2026;178:107971.
    PubMed     Abstract available


    April 2026
  92. ZHAO Z, Guo Y
    Comment on "Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma".
    Oral Oncol. 2026;178:107995.
    PubMed    


  93. BAKHTIAR M, Al-Inaya Y, Das D, Margalit DN, et al
    Clearance of circulating HPV DNA during chemoradiation using a next-generation sequencing liquid biopsy.
    Oral Oncol. 2026;178:107984.
    PubMed     Abstract available


  94. ABOU-FOUL AK, Kristunas C, Henson C, Andrew D, et al
    Correlation between head and neck radiologists reporting on extranodal extension detected on radiological imaging: A head and neck cancer international group multinational study.
    Oral Oncol. 2026;178:107980.
    PubMed     Abstract available


  95. GULMEZ E, Ozdemir AC, Al EA, Kara I, et al
    Evaluation of long-term outcomes of functional suprahyoid neck dissection in patients with early-stage lower lip cancer.
    Oral Oncol. 2026;177:107978.
    PubMed     Abstract available


  96. YOKOTA T, Kiyota N, Kodaira T, Nishino H, et al
    Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial.
    Oral Oncol. 2026;177:107977.
    PubMed     Abstract available


  97. CHEN W, Ye K
    Comment on "Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study".
    Oral Oncol. 2026;177:107972.
    PubMed    


  98. HUANG CC, Hsiao JR, Wang WM, Wang F, et al
    Early diagnosis and treatment of oral cancer in workers was associated with reduced losses of healthy life expectancy and productivity: real-world evidence from Taiwan during 2010-2019.
    Oral Oncol. 2026;177:107969.
    PubMed     Abstract available


  99. RUSSI EG
    Randomizing treatment is not equivalent to validating biomarker-guided intensification in high-risk nasopharyngeal carcinoma.
    Oral Oncol. 2026;177:107970.
    PubMed    


  100. COSSU ROCCA M, Esposito A, Vecchio S, Nicolai P, et al
    A prospective study with Comprehensive Geriatric Assessment (CGA) before curative treatment in older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
    Oral Oncol. 2026;177:107968.
    PubMed     Abstract available


  101. CHAKRABARTY N, Dadlani T, Mahajan A, Laskar SG, et al
    Diagnostic value of MRI-based iENE assessment for predicting major and minor extranodal extension in oral tongue carcinoma.
    Oral Oncol. 2026;177:107960.
    PubMed     Abstract available


  102. ALABEEDI F, Zheng M, Kataria A, Malki MI, et al
    Clinical efficacy of chemopreventive agents in oral cancer and oral potentially malignant disorders: A systematic review.
    Oral Oncol. 2026;177:107961.
    PubMed     Abstract available


  103. BOONE G, Davis KP, Zhang Z, Elledge CR, et al
    Defining platinum-ineligible head and neck cancer patients from administrative data.
    Oral Oncol. 2026;177:107953.
    PubMed     Abstract available


  104. HUANG YJ, Fang KC, Tsai MH, Chuang HC, et al
    Swallowing-related outcomes and organ-at-risk dosimetry after proton versus photon radiotherapy in nasopharyngeal carcinoma.
    Oral Oncol. 2026;175:107906.
    PubMed     Abstract available


  105. CRACCHIOLO JR, Kavanagh F, Starc MT, Scholfield D, et al
    Defining response-adapted surgery after neoadjuvant systemic therapy in sinonasal squamous cell carcinoma.
    Oral Oncol. 2026;175:107882.
    PubMed     Abstract available


  106. PARK H, Kim BR, Yoo JH, Kim SW, et al
    Clinical implication of the 2025 ATA risk stratification in follicular thyroid carcinoma: A comparison with the 2015 ATA risk stratification.
    Oral Oncol. 2026;175:107912.
    PubMed     Abstract available


  107. MANFUSO A, Cirignaco G, Cocis S, Volpe F, et al
    Selective tracheostomy in oral cancer reconstruction with myomucosal flaps: Outcomes and an appraisal of published risk scores.
    Oral Oncol. 2026;175:107916.
    PubMed     Abstract available


  108. NGO DQ, Le DT, Ngo QX, Le QV, et al
    Surgical outcomes of modified versus conventional transoral endoscopic thyroidectomy vestibular approach for papillary thyroid carcinoma.
    Oral Oncol. 2026;175:107908.
    PubMed     Abstract available


    March 2026
  109. YAMADA T, Okuyama K, Hamada A, Yanamoto S, et al
    Interpreting neoadjuvant chemo-immunotherapy through tumor microenvironment dynamics in head and neck cancer.
    Oral Oncol. 2026;176:107958.
    PubMed    


  110. MASCARELLA MA, Mlynarek A, Richardson K, Vendra V, et al
    Predicting treatment intolerance in operable head and neck cancer using the modified head and neck surgery risk index.
    Oral Oncol. 2026;176:107943.
    PubMed     Abstract available


  111. LI J
    Sex-specific immune determinants in head and neck squamous cell carcinoma: bridging preclinical insights to clinical translation.
    Oral Oncol. 2026;176:107950.
    PubMed    


  112. HAN J
    Comment on "Selective tracheostomy in oral cancer reconstruction with myomucosal flaps: Outcomes and an appraisal of published risk scores".
    Oral Oncol. 2026;176:107955.
    PubMed    


  113. DU C, Zhai R, Kong F, Niu X, et al
    Prognostic value of early Epstein-Barr Virus DNA response in patients with locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2026;176:107934.
    PubMed     Abstract available


  114. TOPKAN E, Selek U
    Comment on low-dose fractionated radiotherapy during induction chemotherapy for node-positive locoregionally advanced nasopharyngeal carcinoma: a randomized phase II trial.
    Oral Oncol. 2026;176:107940.
    PubMed    


  115. KASAHARA K, Kono T, Sato Y, Okubo K, et al
    Risk-benefit stratification for immune checkpoint inhibitor therapy in head and neck cancer based on immune-related adverse events and treatment discontinuation using routine clinical indicators beyond PD-L1 expression.
    Oral Oncol. 2026;176:107938.
    PubMed     Abstract available


  116. KOCH N, Yosefof E, Gleber-Netto FO, Amir I, et al
    Elective neck irradiation does not improve regional control or survival in pT3-T4N0 oral cavity SCC after high-yield neck dissection: A retrospective multicenter analysis.
    Oral Oncol. 2026;176:107946.
    PubMed     Abstract available


  117. LEE SF, Hircock C, Yip PL, Cheo T, et al
    Limitations of quality-of-life assessment and long-term side effects in nasopharyngeal carcinoma: a narrative review.
    Oral Oncol. 2026;176:107935.
    PubMed     Abstract available


  118. JAGADEESHA S, Lamenza F, Upadhaya P, Chung C, et al
    Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;176:107929.
    PubMed     Abstract available


  119. DOU K, Liu D, Shi Y, Qin H, et al
    Can the submandibular gland be preserved during neck dissection in patients with oral squamous cell carcinoma?A systematic review and meta-analysis.
    Oral Oncol. 2026;176:107913.
    PubMed     Abstract available


  120. CARVALHO WA, Carvalho AA, Silveira AA
    Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.
    Oral Oncol. 2026;176:107930.
    PubMed     Abstract available


  121. DAI WF, Nguyen L, Liu N, Chan KK, et al
    Corrigendum to "Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study" [Oral Oncol. 173 (2026) 107851].
    Oral Oncol. 2026 Mar 5:107919. doi: 10.1016/j.oraloncology.2026.107919.
    PubMed    


  122. SHIMIZU T, Takahashi H, Tada H, Chikamatsu K, et al
    Integrative analysis of aging-related immune parameters reveals prognostic and immunotherapeutic implications in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;176:107914.
    PubMed     Abstract available


  123. CHU F, Benzi P, Tagliabue M, Mossinelli C, et al
    Rare laryngeal tumors: A retrospective bicentric study on 74 patients and systematic review.
    Oral Oncol. 2026;174:107852.
    PubMed     Abstract available


  124. WOJTERA BP, Beharry A, Salati V, Lambercy K, et al
    Long-term swallowing outcomes following transoral robotic surgery for oropharyngeal cancer - Five years and beyond.
    Oral Oncol. 2026;174:107876.
    PubMed     Abstract available


    February 2026
  125. ZHAO ZY, He SQ, Liu GY, Lv SH, et al
    Efficacy of radiotherapy to metastatic lesion in de novo metastatic nasopharyngeal carcinoma patients: A multicenter, propensity score matching study.
    Oral Oncol. 2026;175:107907.
    PubMed     Abstract available


  126. NTOUKAS SM, Mohamad N, Boparai R, Dennett L, et al
    Effects of exercise on health-related fitness and patient-reported outcomes in survivors of head and neck cancer: a systematic review and meta-analysis.
    Oral Oncol. 2026;175:107902.
    PubMed     Abstract available


  127. BHATI M, Bagchi P, Pawar P, Baviskar P, et al
    Aberrant lateral position of external carotid artery, a surgical pitfall during neck dissection.
    Oral Oncol. 2026;175:107905.
    PubMed    


  128. HOLGADO A, Llansana A, Vazquez C, Gallego O, et al
    Identification of prognostic variables in patients with recurrent head and neck squamous cell carcinoma treated with salvage surgery: Implications for treatment with immunotherapy.
    Oral Oncol. 2026;175:107903.
    PubMed     Abstract available


  129. ECONOMOPOULOU P, Pouliakis A, Kyprianou M, Pantazopoulos A, et al
    An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion).
    Oral Oncol. 2026;175:107900.
    PubMed     Abstract available


  130. MARGONI A, Papavassiliou KA, Papavassiliou AG
    From heterogeneity to molecular stratification: A multiplex genomic panel for tailored therapy of head and neck squamous cell carcinoma.
    Oral Oncol. 2026;175:107904.
    PubMed     Abstract available


  131. LI C, Xiao X, Jiang H, Li B, et al
    Comparable survival after lobectomy and total thyroidectomy for T3b differentiated thyroid carcinoma: A population-based study.
    Oral Oncol. 2026;175:107891.
    PubMed     Abstract available


  132. XIN Y, Yang L, Liu C, Li D, et al
    Spatial transcriptomics of immune ecotypes for predicting immunotherapy outcomes in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;175:107887.
    PubMed     Abstract available


  133. FAN M, Yin Q, Li L, Lian Q, et al
    Low-dose fractionated radiotherapy combined with induction chemotherapy in high-risk nasopharyngeal carcinoma: An open-label, randomized phase 2 trial.
    Oral Oncol. 2026;175:107888.
    PubMed     Abstract available


  134. BENITES C, White C, Balaguru L, Gonghao L, et al
    Does discharge location following head and neck cancer surgery affect quality outcomes?
    Oral Oncol. 2026;175:107879.
    PubMed     Abstract available


  135. SINGH SP, Prasad S, Dean PM, Kujur AL, et al
    Prognostic significance of extranodal extension in cervical lymph node metastases of head and neck squamous cell carcinoma: A systematic review and meta-analysis with bibliometric overview.
    Oral Oncol. 2026;174:107862.
    PubMed     Abstract available


  136. ZHANG L
    Comment on "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery".
    Oral Oncol. 2026;174:107881.
    PubMed    


  137. ROY P, Weber MB, Gupta R, Kakkar A, et al
    The prognostic significance of the 'Worst Pattern of Invasion' in oral cancers-an international collaborative multicentre analysis.
    Oral Oncol. 2026;174:107874.
    PubMed     Abstract available


  138. TAKAHASHI Y, Bell D, Corona A, Su SY, et al
    Establishment of novel stable human sinonasal NUT carcinoma cell lines.
    Oral Oncol. 2026;173:107828.
    PubMed     Abstract available


    January 2026
  139. HACK S, Karni RJ, Maniaci A, Fundakowski CE, et al
    Evaluation of large language models as decision support tools for head and neck cancer management: A blinded multidisciplinary simulation study.
    Oral Oncol. 2026;174:107877.
    PubMed     Abstract available


  140. WANG N, Gao H, Yu SX, Fan J, et al
    The first report of contralateral parapharyngeal space metastasis of papillary thyroid carcinoma: report of a case.
    Oral Oncol. 2026;174:107865.
    PubMed    


  141. ZHONG J, Chen H, Yan Z, Xu H, et al
    Refinement of N category in version-nine of AJCC/UICC TNM staging system for nasopharyngeal carcinoma based on the international consensus recommendations for diagnosing extranodal extension.
    Oral Oncol. 2026;174:107866.
    PubMed     Abstract available


  142. ALMEIDA ND, Schrand TV, Sullivan D, Yu H, et al
    Prognostic associations of systemic inflammation response index (SIRI) in patients with head and neck cancer: a systematic review and meta-analysis.
    Oral Oncol. 2026;174:107859.
    PubMed     Abstract available


  143. LOVETT JT, Wotman MT, Westra WH, Ahn S, et al
    Long-Term outcomes of induction chemotherapy-guided reduced-dose chemoradiotherapy in poor-risk HPV-Positive oropharyngeal Cancer: Results from the sequential quarterback trials.
    Oral Oncol. 2026;174:107858.
    PubMed     Abstract available


  144. CHENG C, Zhang J
    Advancing methodological rigor in exercise oncology trials for head and neck cancer.
    Oral Oncol. 2026;173:107857.
    PubMed    


  145. CAROSI F, Demurtas S, Ciarfella A, Orlandi E, et al
    Perioperative immunotherapy for head and neck cancer: from early successes to clinical challenges in relapsed and/or metastatic disease.
    Oral Oncol. 2026;173:107853.
    PubMed    


  146. WANG W, Lou Y
    From risk factors to clinical Decisions: Methodological Considerations in Predicting occult metastasis in papillary thyroid carcinoma.
    Oral Oncol. 2026;173:107854.
    PubMed    


  147. SOBY S, Mortensen D, Gothelf A, Gyldenkerne N, et al
    Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study.
    Oral Oncol. 2026;173:107849.
    PubMed     Abstract available


  148. DAI WF, Nguyen L, Liu N, Chan KK, et al
    Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study.
    Oral Oncol. 2026;173:107851.
    PubMed     Abstract available


  149. MARGONI A, Papavassiliou KA, Papavassiliou AG
    Harnessing TP53 mutational status to enhance prognostic precision and therapeutic effectiveness in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;173:107846.
    PubMed    


  150. WU WJ, An PG, Zhang ZQ, Shen LH, et al
    Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: A single-arm phase II clinical trial.
    Oral Oncol. 2026;172:107809.
    PubMed     Abstract available


  151. NIU S, Ding J, Chen H, Zhu Z, et al
    Positron emission tomography-based intratumoral spatial diversity for prognosis in nasopharyngeal carcinoma.
    Oral Oncol. 2026;173:107845.
    PubMed     Abstract available


    December 2025
  152. XIAO G, Ning L, Chen L, Zhang S, et al
    Exercise and quality of life in head and neck squamous cell carcinoma patients receiving neoadjuvant immuno-chemotherapy: A randomized, open-labeled phase II trial.
    Oral Oncol. 2025;173:107844.
    PubMed     Abstract available


  153. JAKOBSEN KK, H Rasmussen J, Melchiors J, Agander TK, et al
    Head and neck cancer trends in Denmark: A nationwide, 40-Year data analysis.
    Oral Oncol. 2025;173:107843.
    PubMed     Abstract available


  154. LECHIEN JR, Paleri V, Baudouin R, Brunet A, et al
    European surgical guidelines: transoral robotic surgery for head and neck cancers.
    Oral Oncol. 2025;173:107826.
    PubMed     Abstract available


  155. CHAUDHRY M, Elfar A, Rowsey K, Neel A, et al
    Safety reporting in head and neck squamous cell carcinoma clinical Trials: A comparative analysis of ClinicalTrials.gov data and published research.
    Oral Oncol. 2025;173:107840.
    PubMed     Abstract available


  156. ZHANG M, Song J, Yuan Y, Cao X, et al
    Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.
    Oral Oncol. 2025;173:107841.
    PubMed     Abstract available


  157. PARK SE, Hong SH, Park JO, Kim SY, et al
    Head and neck squamous cell carcinoma following allogeneic bone marrow transplantation: Clinical features, genomic Alterations, and limited efficacy of palliative chemotherapy.
    Oral Oncol. 2025;173:107827.
    PubMed     Abstract available


  158. THIAGARAJAN S, Rukmangathan T, Sharma D, Kakade A, et al
    Prevalence, risk Factors, and quality of life in patients with head and neck lymphedema following treatment for head and neck Cancer: The HeNLy-1 study.
    Oral Oncol. 2025;173:107838.
    PubMed     Abstract available


  159. LIU Q, Wei JN, Zhou JY, Zhang CR, et al
    Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma.
    Oral Oncol. 2025;173:107825.
    PubMed     Abstract available


  160. ZOU C
    Letter to the editor: Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort.
    Oral Oncol. 2025;172:107705.
    PubMed    


  161. CHOW VL, Ho VW, Lo AS
    Trans-hairline robotic neck dissection and robotic microvascular free flap reconstruction in oral cavity cancer.
    Oral Oncol. 2025;172:107819.
    PubMed     Abstract available


  162. YOON HN, Kim JH, Gu D, Lee J, et al
    Patient-derived 3D organoid platform for functional assessment of GPC3-targeted CAR T cell cytotoxic activity in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;172:107814.
    PubMed     Abstract available


  163. SHAIKH MH, Gazala W, Zeng C, Naimi MF, et al
    NOTCH1 loss promotes chemo and radio-resistance in head and neck cancer.
    Oral Oncol. 2025;172:107815.
    PubMed     Abstract available


  164. HACK S, Attal R, Geva K, Farzad A, et al
    Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer.
    Oral Oncol. 2025;172:107813.
    PubMed     Abstract available


  165. BARAN E, Lee M, Kamalraj P, Karam I, et al
    Cancer stage documentation and accuracy: Single-center retrospective study on oropharyngeal cancers.
    Oral Oncol. 2025;171:107795.
    PubMed     Abstract available


  166. CHELVARAJAH RC, Huang SH, Su J, Gete M, et al
    Outcomes and characteristics of patients receiving pre-operative versus post-operative radiotherapy for sinonasal squamous cell carcinoma.
    Oral Oncol. 2025;171:107794.
    PubMed     Abstract available


  167. CHONG CY, Young RJ, Lim AM, Pizzolla A, et al
    Evaluating CD103(+) intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer.
    Oral Oncol. 2025;171:107792.
    PubMed     Abstract available


  168. HIDALGO CM, Hernandez-Herrera GA, Day CN, Olawuni F, et al
    Access to surgery and high-quality radiotherapy for human papillomavirus related oropharynx cancer.
    Oral Oncol. 2025;171:107768.
    PubMed     Abstract available


    November 2025
  169. LECHIEN JR
    Learning process of transoral robotic surgery for head and neck cancers: a scoping review.
    Oral Oncol. 2025;171:107788.
    PubMed     Abstract available


  170. LI M, Zhou Y, Cai M
    Letter to the Editor: A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2025;171:107784.
    PubMed    


  171. OKURA M, Yamakawa N, Otsuru M, Hasegawa T, et al
    T4a classification for oral cancer using mandibular canal invasion instead of bone marrow invasion in the TNM staging system.
    Oral Oncol. 2025;171:107771.
    PubMed     Abstract available


  172. DOERFLER R, Chen J, Kim C, Smith JD, et al
    Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer.
    Oral Oncol. 2025;171:107742.
    PubMed     Abstract available


  173. DIEZ-FRAILE A, Pottel L, Lamoral P, De Backer T, et al
    Age and surgical complexity outperform preoperative Geriatric-8 for 30-day major complications in older head and neck cancer.
    Oral Oncol. 2025;171:107774.
    PubMed    


  174. VAN LOOCKE P, Beuselinck B, Meulemans J, Nuyts S, et al
    Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort study.
    Oral Oncol. 2025;171:107772.
    PubMed    


  175. TIRELLI G, Boscolo-Rizzo P
    Perioperative pembrolizumab and the changing paradigm of adjuvant therapy in head and neck squamous cell carcinoma: the case of T1-2, pN1.
    Oral Oncol. 2025;171:107770.
    PubMed    


  176. MASO V, Lechien JR, Gengler I, Chiesa-Estomba C, et al
    Management of head and neck cancer around the world: an international survey by the world ear, nose, and throat federation.
    Oral Oncol. 2025;171:107766.
    PubMed     Abstract available


  177. WILLIAMS MM, Hanna GJ, Sethi RK, Rettig EM, et al
    Outcomes of oropharyngeal squamous cell carcinoma among patients with lymphoproliferative disorders.
    Oral Oncol. 2025;170:107761.
    PubMed     Abstract available


  178. LI R, Ma S, Tang T, Zhao Y, et al
    Prognostic impact and risk factors of level IV/V lymph nodes metastasis in laryngeal squamous cell carcinoma.
    Oral Oncol. 2025;170:107758.
    PubMed     Abstract available


  179. ZHU AQ, Cassianni CE, Haller T, O'Byrne TJ, et al
    Sensitivity of post-treatment surveillance in detecting recurrence and metastasis in surgically treated HPV-positive oropharyngeal squamous cell carcinoma patients.
    Oral Oncol. 2025;171:107767.
    PubMed     Abstract available


    October 2025
  180. BERTIN B, Kowalski LP, Matos LL
    The low evidence to treat elderly patients with head and neck cancer.
    Oral Oncol. 2025;171:107764.
    PubMed     Abstract available


  181. XIANG N, Li W
    Re: "Patterns of care in de?novo oligo?metastatic and oligo?recurrent head and neck cancers: A HNCIG survey" (Oral oncology).
    Oral Oncol. 2025;171:107749.
    PubMed    


  182. DAS R, Misra SR, Mohapatra SSG
    Refining prognosis and Personalizing Therapy: A Step Forward with Machine learning in HPV-Associated head and neck cancer.
    Oral Oncol. 2025;170:107752.
    PubMed    


  183. LIANG H, Guo Y
    Comment on "Massive nasal bleeding in nasopharyngeal carcinoma": Risk stratification and clinical implications.
    Oral Oncol. 2025;170:107755.
    PubMed    


  184. HELOU V, Abdul-Rahman NH, Loo SK, Gao SJ, et al
    Circulating tumor DNA in Non-Viral head and neck squamous cell Carcinoma: A systematic review and Meta-Analysis.
    Oral Oncol. 2025;170:107760.
    PubMed     Abstract available


  185. WANG Q, Yang Q, Wang Z, Duan X, et al
    Efficacy of primary lesion re-irradiation in nasopharyngeal carcinoma with synchronous recurrence and distant metastasis.
    Oral Oncol. 2025;170:107743.
    PubMed     Abstract available


  186. KANG SK, Brooks E, Wolk R, Siriruchatanon M, et al
    Assessing liquid biopsy tests for the detection of head and neck squamous cell carcinoma: an umbrella review.
    Oral Oncol. 2025;170:107535.
    PubMed     Abstract available


  187. BOIDE A, Glasmacher AR, Wurschi G, Tews AM, et al
    Fear of cancer recurrence in adults with p16-positive head and neck cancer after radiotherapy - Results from a multicenter cross-sectional observational study.
    Oral Oncol. 2025;170:107757.
    PubMed     Abstract available


  188. HONG MH, Lee S, Kim CG, Son W, et al
    A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107745.
    PubMed     Abstract available


  189. JEYARAJ G
    Commentary on "Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma".
    Oral Oncol. 2025 Oct 10:107741. doi: 10.1016/j.oraloncology.2025.107741.
    PubMed    


  190. MARUDHUPANDI T
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;170:107746.
    PubMed     Abstract available


  191. LI Y, Tong S, Tian J, You X, et al
    Comment on: "Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial".
    Oral Oncol. 2025;170:107729.
    PubMed    


  192. LI S, Garb BF, Qin T, Soppe SE, et al
    Tumor subtype classification tool for HPV-associated head and neck cancers.
    Oral Oncol. 2025;170:107726.
    PubMed     Abstract available


  193. SWAIN M, Ghosh-Laskar S, McDowell L, Henson C, et al
    Patterns of care in de-novo oligo-metastatic and oligo-recurrent head and neck cancers: A Head and Neck Cancer International Group (HNCIG) Survey.
    Oral Oncol. 2025;170:107647.
    PubMed     Abstract available


  194. VARETA JA, Zhang X, Kuhnell D, Hagen MC, et al
    Characterizing the mutational landscape of sinonasal squamous cell carcinoma using whole-exome sequencing.
    Oral Oncol. 2025;169:107694.
    PubMed     Abstract available


  195. HAGREN A, Sjovall J, Brogardh C, Johansson K, et al
    Head and neck lymphedema after radiotherapy - Prevalence, changes and associated factors - a prospective observational cohort study.
    Oral Oncol. 2025;169:107671.
    PubMed     Abstract available


  196. HINTZE JM, Cleere E, Timon C, Kinsella J, et al
    The lymph node ratio is a prognostic factor for survival in laryngeal and hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107625.
    PubMed     Abstract available


  197. SIQUEIRA JM, Heguedusch D, Cunha MT, de Sousa LG, et al
    Exploring TROP2 expression in oropharyngeal squamous cell carcinoma: Association with prognosis and tumor immune microenvironment composition.
    Oral Oncol. 2025;169:107634.
    PubMed     Abstract available


  198. HOUCINE Y, Kedous S, Kamoun S, Methnani A, et al
    Nasopharyngeal low-grade papillary Adenocarcinoma: A rare entity with diagnostic challenges.
    Oral Oncol. 2025;169:107612.
    PubMed     Abstract available


  199. KUMARAGURU S, Pandiyan R
    Letter to the Editor: Clinical significance of HPV16 in oropharyngeal cancer: a commentary on recent evidence.
    Oral Oncol. 2025;169:107550.
    PubMed     Abstract available


  200. MARUDHUPANDI T
    Letter to the Editor: Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
    Oral Oncol. 2025;170:107731.
    PubMed     Abstract available


  201. MARUDHUPANDI T
    Letter to the editor: Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107730.
    PubMed     Abstract available


    September 2025
  202. MISRA SR, Das R
    Palliative care integration in head and neck Cancer: Bridging the gap between evidence and practice.
    Oral Oncol. 2025;170:107735.
    PubMed    


  203. MISRA SR, Das R, Giri M
    Commentary on "pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial".
    Oral Oncol. 2025;170:107701.
    PubMed    


  204. ANNAMALAI A
    Comments on, "Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study".
    Oral Oncol. 2025;170:107716.
    PubMed    


  205. ZHANG M
    Comment on "Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma".
    Oral Oncol. 2025;170:107722.
    PubMed    


  206. HUANG S, Liao D, Zhu X, Feng Y, et al
    Advancing oral cancer equity in India novel pathways for screening impact.
    Oral Oncol. 2025;170:107696.
    PubMed    


  207. LI M, Zhou Y, Cai M
    Letter to the Editor: Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107725.
    PubMed    


  208. MISRA SR, Das R
    Esophageal dysmotility in head and neck cancer survivors: a critical step forward and the path ahead!
    Oral Oncol. 2025;170:107718.
    PubMed    


  209. DUAN Y
    Comments on: Stroke risk after head and neck cancer diagnosis and treatment in a real-world clinical cohort.
    Oral Oncol. 2025;170:107717.
    PubMed    


  210. AL MAQRASHI ZAA, Kartolo A, Meyers BM
    Resectable locally advanced head and neck squamous cell carcinoma: cut first or immune checkpoint inhibitors first?
    Oral Oncol. 2025;170:107704.
    PubMed    


  211. CHENG H, Jiang M, Kim S, Moshiri A, et al
    Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107687.
    PubMed     Abstract available


  212. MISRA SR, Das R
    Financial instability, insurance, and transportation barriers in oral cancer care: contrasting perspectives between the United States and India.
    Oral Oncol. 2025;169:107692.
    PubMed    


  213. SAMUEL M
    Disparities in oral cancer screening in India: reflections on NFHS 5 evidence and pathways forward.
    Oral Oncol. 2025;169:107693.
    PubMed     Abstract available


  214. SINDYA J, Rajanathadurai J, Perumal E
    Reflections on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025;169:107691.
    PubMed    


  215. SASIKALA S, Sowmiya A, Usharani N
    Letter to the Editor: Salivary DNA methylation derived estimates of biological Aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2025;169:107668.
    PubMed    


  216. LUO L, Lu C, Feng H
    Refining SCCUP management: towards safe de-escalation in HPV-positive head and neck cancer-letter on Barrett et al.
    Oral Oncol. 2025;169:107681.
    PubMed    


  217. VENKATACHALAM DK, Kanimozhi K
    Letter to the Editor "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025;169:107679.
    PubMed    


  218. MISRA SR, Das R
    The imperative of careful selection and novel strategies: Comment on Mrosk et al.'s outcomes of primary chemoradiation for advanced oral cancer.
    Oral Oncol. 2025;169:107676.
    PubMed    


  219. LOVETT JT, Westra WH, Roof S, Bakst RL, et al
    Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: long-term follow-up of the quarterback de-escalation trials.
    Oral Oncol. 2025;169:107654.
    PubMed     Abstract available


  220. KUMAR GN, Sangeetha S
    Comment on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025 Sep 8:107666. doi: 10.1016/j.oraloncology.2025.107666.
    PubMed    


  221. XIAO X, Liu T, Song Y, Lu M, et al
    Evaluation on the prognostic significance of cervical occult metastasis in cN0 glottic laryngeal cancer.
    Oral Oncol. 2025;169:107648.
    PubMed    


  222. ZHANG D, Zhang J, Cai M
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107660.
    PubMed    


  223. ZHANG D, Zhang P, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107661.
    PubMed    


  224. DUAN Y
    Letter to the Editor: Oral cancer screening in India: A secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107657.
    PubMed    


  225. ZHANG D, Zhou Y, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107659.
    PubMed    


  226. MISRA SR, Das R
    Critical appraisal of "Oral cancer screening in India: A secondary analysis of disparities using national family health survey data".
    Oral Oncol. 2025;169:107653.
    PubMed    


  227. PENG X, Xie Y, Liu Y
    Comment on "Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics".
    Oral Oncol. 2025;169:107644.
    PubMed    


  228. BATOOL S, Hansen EE, Sethi RKV, Rettig EM, et al
    Financial instability, insurance, and transportation influence timely head and neck cancer care in the United States: Patient and healthcare worker perspectives.
    Oral Oncol. 2025;169:107607.
    PubMed     Abstract available


  229. DUNN LA, Ho AL, Michel LS, Wong W, et al
    A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2025;169:107524.
    PubMed     Abstract available


  230. NOEL CW, Birkenbeuel J, Ozer E, Agrawal A, et al
    Patterns of referral and outcomes in oropharyngeal cancer management.
    Oral Oncol. 2025;168:107602.
    PubMed     Abstract available


  231. GILI R, Morbini P, Bossi P
    PD-L1 Expression in head and neck squamous cell carcinoma: qualitative or quantitative assessment? Is that enough or we need something more?
    Oral Oncol. 2025;168:107606.
    PubMed     Abstract available


  232. YANG J, Wu W, Liu J, Li J, et al
    Comprehensive integration of single-cell and bulk transcriptome to reveal plasma cell heterogeneity and a prognosis signature in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;168:107595.
    PubMed     Abstract available


  233. KLEEBAYOON A, Wiwanitkit V
    Semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD): correspondence.
    Oral Oncol. 2025;169:107645.
    PubMed    


  234. BHAGIA P, Mukherjee A, Agarwal T, Giri S, et al
    Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort: Running title: Treatment in a Real-World clinical cohort.
    Oral Oncol. 2025;169:107599.
    PubMed     Abstract available


    August 2025
  235. BARRETT TF, Apicelli AJ, Ramadan S, Pipkorn P, et al
    Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation.
    Oral Oncol. 2025;169:107631.
    PubMed     Abstract available


  236. ANSARI E, Carrillo Minulina N, van Es RJJ, Dieleman FJ, et al
    Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients.
    Oral Oncol. 2025;169:107628.
    PubMed     Abstract available


  237. DAI Y, Li W
    Comment on "Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD)" by Schroter et al.
    Oral Oncol. 2025;169:107640.
    PubMed    


  238. KANA L, Chamma B, Robinette N, Cramer JD, et al
    Pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial.
    Oral Oncol. 2025;169:107633.
    PubMed     Abstract available


  239. HUANG J, Yan X, Wang S, Huang S, et al
    Improvements to the LEF Self-Management study for head and neck cancer survivors - Letter on Deng et al.
    Oral Oncol. 2025;169:107639.
    PubMed    


  240. CAO J, Han W, Liu Y
    Letter to the editor: effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;169:107624.
    PubMed    


  241. HUANG X, Gu X
    Comment on Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;169:107626.
    PubMed    


  242. MISRA SR, Das R
    Insights on: "Social health at 5 years after diagnosis in head and neck cancer Survivors".
    Oral Oncol. 2025;169:107637.
    PubMed    


  243. BOSSI P, Kiyota N, Mesia R, Rosenberg AJ, et al
    Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2025;169:107596.
    PubMed     Abstract available


  244. TANG Y, Jin Q, Gan X
    Comment on "Social health at 5 years after diagnosis of head and neck cancer".
    Oral Oncol. 2025;169:107627.
    PubMed    


  245. RAHMAN R, Sheikh I, Merchant Y, Mathur A, et al
    Oral cancer screening in India: a secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107632.
    PubMed     Abstract available


  246. DAI Y, Li WJ
    Comment on "Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial" by Deng J et al.
    Oral Oncol. 2025;169:107613.
    PubMed    


  247. CHEN Y, Yan Y
    Comment on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
    Oral Oncol. 2025;169:107614.
    PubMed    


  248. LUO R, Wu J, Zhong W, Ai K, et al
    Letter to the editor - Commentary on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
    Oral Oncol. 2025;169:107610.
    PubMed    


  249. ZHANG J, Liu DM
    Advancing self-management for head and neck cancer-related lymphedema: A promising step forward.
    Oral Oncol. 2025;169:107611.
    PubMed     Abstract available


  250. SCHROTER P, Christ LV, Dvornikovich K, Stritzke F, et al
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107604.
    PubMed     Abstract available


  251. TANG M, Dougherty M, Worona L, Ramos E, et al
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107608.
    PubMed     Abstract available


  252. COLAK G, Demir B
    Letter to the Editor: "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
    Oral Oncol. 2025;168:107579.
    PubMed    


  253. TOSONI A, Di Nunno V, Carlini A, Gatto L, et al
    The role of systemic therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma progressed to immunotherapy: A systematic review and meta analysis.
    Oral Oncol. 2025;168:107582.
    PubMed     Abstract available


  254. ASHOK A, Dimitri S, Plonowska-Hirschfeld K, Wu MP, et al
    Establishing an integrated approach to head and neck cancer treatment and prevention: The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center Model.
    Oral Oncol. 2025;168:107591.
    PubMed     Abstract available


  255. LAVANYA K, Sathishkumar K, Nallusamy D
    Letter to the editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107590.
    PubMed    


  256. HONGO T, Hirano Y, Tarutani Y, Omori H, et al
    Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
    Oral Oncol. 2025;168:107585.
    PubMed     Abstract available


  257. KOKER G, Ozcelik G
    Comment on: "Cisplatin ototoxicity and hydration schedules''.
    Oral Oncol. 2025;168:107545.
    PubMed    


  258. DENG J, Murphy BA, Andersen LP, McMenamin E, et al
    Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial.
    Oral Oncol. 2025;168:107556.
    PubMed     Abstract available


  259. SUDARSON J
    Commentary on "molecular features of T and N stage progression in laryngeal cancer".
    Oral Oncol. 2025;168:107587.
    PubMed     Abstract available


  260. YU Z, Zhuang Z, Zhao X, Chi H, et al
    Advancing AI-driven pathology in oral cancer: opportunities for enhanced TIL assessment and clinical integration.
    Oral Oncol. 2025;168:107586.
    PubMed    


  261. ASHOKKUMAR K
    Letter to the editor - a preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107580.
    PubMed    


  262. KRISHNAN M, Jothishanmugam A, Mari A, Babu S, et al
    Preserving the mandible, protecting the patient: A commentary on fracture risk following marginal mandibulectomy in head and neck cancer.
    Oral Oncol. 2025;168:107575.
    PubMed    


  263. MATSUDA Y, Fujioka-Kobayashi M, Tatsumi H, Osako-Sonoyama R, et al
    Factors associated with postoperative oral dysfunction in patients with oral cancer: a structural equation modeling study.
    Oral Oncol. 2025;168:107577.
    PubMed     Abstract available


  264. MULARONI F, Marchi F, Gaudioso P, Taboni S, et al
    Selected laryngeal squamous cell carcinomas with laryngeal mobility impairment are suitable for curative larynx-preservation treatment: A multi-institutional study on 406 patients from the ARYFIX collaborative group.
    Oral Oncol. 2025;167:107466.
    PubMed     Abstract available


  265. MORES AL, Lima de Araujo CA, de Freitas Busnardo F, Cardili L, et al
    Cutaneous metastasis of oropharyngeal squamous cell carcinoma: A case report.
    Oral Oncol. 2025;167:107438.
    PubMed     Abstract available


  266. SEDASSARI BT, Celin MF, Pigatti FM
    SMARCB1-deficient sinonasal carcinoma with oral involvement: A potential mimicker of salivary-type carcinomas.
    Oral Oncol. 2025;167:107435.
    PubMed     Abstract available


  267. TONSBEEK AM, Hundepool CA, van der Oest M, Offerman MPJ, et al
    Life following total laryngectomy: mixed-model analyses of longitudinal patient-reported outcomes in a prospective cohort.
    Oral Oncol. 2025;167:107431.
    PubMed     Abstract available


  268. PERYASSU BC, Nicolau-Neto P, da Costa EWE, Santos IC, et al
    Assessing the prognostic significance and predictive features of cervical occult metastasis in glottic laryngeal squamous cell carcinoma.
    Oral Oncol. 2025;167:107429.
    PubMed     Abstract available


  269. DOLL C, Hofmann E, Trelinska-Finger A, Heiland M, et al
    Benefit from adjuvant radiotherapy in early-stage oral cavity and oropharyngeal cancer with solitary ipsilateral lymph node metastasis - A population-based study on German cancer registry data.
    Oral Oncol. 2025;167:107384.
    PubMed     Abstract available


  270. GUZZO M, Bianchi R, Colombo S, Santamato F, et al
    Mandibular swing approach: 25 years of experience at Istituto Nazionale Tumori of Milan.
    Oral Oncol. 2025;167:107405.
    PubMed     Abstract available


  271. TONG JY, Brimanson K, Moyer K, Wolf J, et al
    Margin analysis of radical tonsillectomy specimens following transoral robotic surgery.
    Oral Oncol. 2025;167:107403.
    PubMed     Abstract available


  272. LUNA-ORTIZ K, Guillen-Hernandez GA, Cano-Valdez AM, Alvarez-Avitia MA, et al
    Poorly differentiated ceruminous adenocarcinoma of the external auditory canal: Letter to the editor.
    Oral Oncol. 2025;168:107544.
    PubMed    


  273. JENNIFER LG, Larnaudie A, Bene MC, Cocherie T, et al
    Relationships between oral microbiome and head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2025;168:107571.
    PubMed     Abstract available


  274. HUMBERT M, Perreard M, Licaj I, Bouhnik AD, et al
    Social health at 5 years after diagnosis of head and neck cancer.
    Oral Oncol. 2025;168:107567.
    PubMed     Abstract available


    July 2025
  275. ELIA A, Tirosh O, Dinstag G, Gugel L, et al
    Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics.
    Oral Oncol. 2025;168:107536.
    PubMed     Abstract available


  276. LI Y, Xiao L, Xie R
    Mitigating survival disparities in head and neck cancer: urgent need to reduce ED-based biopsy delays.
    Oral Oncol. 2025;168:107549.
    PubMed    


  277. SHARFUNNISA SH
    Letter to the editor "reframing nutritional support in head and neck cancer: insights from a prospective cohort study".
    Oral Oncol. 2025;168:107563.
    PubMed    


  278. ZHANG D, Cai M
    Letter to the Editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107558.
    PubMed    


  279. RAJASEKAR A
    Letter to the Editor: HCV infection in head and neck cancer patients: Implications for screening and prognosis in a low prevalence setting.
    Oral Oncol. 2025;168:107561.
    PubMed     Abstract available


  280. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
    Oral Oncol. 2025 Jul 27:107510. doi: 10.1016/j.oraloncology.2025.107510.
    PubMed    


  281. KRISHNAN M, Babu S
    Commentary on Lee et al: From crisis to diagnosis: redefining the emergency department's role in head and neck cancer detection.
    Oral Oncol. 2025;168:107546.
    PubMed    


  282. PENG J, Liang Z, Wang J, Wang G, et al
    Comment on effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;168:107537.
    PubMed    


  283. KRISHNAN M, Babu S
    Letter to the editor: redefining surgical paradigms in isthmic papillary thyroid carcinoma: a timely reappraisal.
    Oral Oncol. 2025;168:107562.
    PubMed    


  284. NARENKUMAR J, Parthipan P
    Letter to the Editor: Impact of the COVID-19 pandemic on diagnosis and disease stage in HPV-positive oropharyngeal cancer: insights and future directions.
    Oral Oncol. 2025;168:107541.
    PubMed     Abstract available


  285. D'ANDREA C, Marhic A, Leveque E, Thureau S, et al
    Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study.
    Oral Oncol. 2025;168:107512.
    PubMed     Abstract available


  286. BABU S, Krishnan M, Ravi PS
    "Commentary on: Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction".
    Oral Oncol. 2025;168:107552.
    PubMed    


  287. KRISHNAN M, Chawla KK, Babu S, D S, et al
    Letter to the editor: Molecular stratification in papillary thyroid carcinoma: Should RET fusions redefine aggressiveness in the post-BRAF era?
    Oral Oncol. 2025;168:107543.
    PubMed    


  288. MORCOM CR, Williams CMD, Al-Qadami G, Vieyra CP, et al
    The biological mechanisms underpinning nutritional and health-related consequences of mucositis in head and neck cancer - A review.
    Oral Oncol. 2025;168:107548.
    PubMed    


  289. ARULMOORTHY MP
    Navigating the diagnostic delay: optimizing timely biopsy and integrating NIR-based technologies for head and neck cancer.
    Oral Oncol. 2025;168:107518.
    PubMed     Abstract available


  290. SHARFUNNISA SH, Rahmathullah A
    Letter to the editor "Integrating nutritional profiling into immunotherapy: A modifiable predictor of outcomes in head and neck Cancer".
    Oral Oncol. 2025;168:107539.
    PubMed    


  291. BABU S, Solomon A, Krishnan M
    Commentary on "Massive nasal bleeding in nasopharyngeal carcinoma: Incidence, risk predictors, and survival impact".
    Oral Oncol. 2025;168:107528.
    PubMed    


  292. JEYARAJ G
    Commentary on, "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
    Oral Oncol. 2025;168:107532.
    PubMed    


  293. ABILAJI S, Parthipan P
    Letter to the Editor: Evaluating the risk-modifying effects of HSV-1 and HSV-2 on head and neck cancer in relation to tobacco, alcohol, and HPV-16.
    Oral Oncol. 2025;168:107516.
    PubMed     Abstract available


  294. CHAWLA JPS, Madan GK
    Comment on "Current status of circulating tumour DNA and circulating cell alterations in HPV-associated head and neck cancer".
    Oral Oncol. 2025;168:107526.
    PubMed    


  295. ZHU J, Xu J, Qu H, Hao J, et al
    A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107511.
    PubMed     Abstract available


  296. LEE MY, Huynh JD, Kim DD, Sunwoo JB, et al
    Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;168:107467.
    PubMed     Abstract available


  297. YANG Z, Lin B, Xie R
    Microvascular tongue reconstruction in oral cancer: Long-term functional outcomes and quality of life considerations.
    Oral Oncol. 2025;167:107490.
    PubMed    


  298. ZHANG Y, Liang R, Lai P
    Comment on "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
    Oral Oncol. 2025;167:107491.
    PubMed    


  299. JEYARAJ G
    Commentary on, "Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: Surgical and oncological outcomes.".
    Oral Oncol. 2025;167:107487.
    PubMed    


  300. RAJATHIRAJAN SD
    Commentary on, "Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study".
    Oral Oncol. 2025;167:107483.
    PubMed    


  301. JEYARAJ G
    Commentary on, "Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact.".
    Oral Oncol. 2025;167:107488.
    PubMed    


  302. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
    Corrigendum to "Massive nasal bleeding in nasopharyngeal carcinoma: incidence, risk predictors, and survival impact" [Oral Oncol. 167 (2025) 107456].
    Oral Oncol. 2025 Jul 4:107465. doi: 10.1016/j.oraloncology.2025.107465.
    PubMed    


  303. RAJATHIRAJAN SD
    Commentary on, "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors".
    Oral Oncol. 2025;167:107472.
    PubMed    


  304. HU A, Wen X, Tian J, Wang Z, et al
    RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma.
    Oral Oncol. 2025;167:107464.
    PubMed     Abstract available


  305. RIJKEN JA, de Ridder M, Devriese LA, Breimer GE, et al
    Long-term survival after multimodal treatment of sinonasal NUT carcinoma: a case report.
    Oral Oncol. 2025;166:107392.
    PubMed     Abstract available


  306. RONDI P, Mattavelli D, Rampinelli V, Schreiber A, et al
    The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2.
    Oral Oncol. 2025;166:107388.
    PubMed     Abstract available


  307. SOMAY E, Bascil S, Topkan E, Selek U, et al
    Re: "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors" by Kamel et al.
    Oral Oncol. 2025;167:107457.
    PubMed    


    June 2025
  308. MALGAVE DS, Hartman CM, Kramer JR, Richardson PA, et al
    Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study.
    Oral Oncol. 2025;167:107446.
    PubMed     Abstract available


  309. ABILAJI S, Narenkumar J
    Letter to the Editor: Enhancing early detection of HPV associated oropharyngeal cancer: a comparative study of NGS, ddPCR, and qPCR.
    Oral Oncol. 2025 Jun 27:107461. doi: 10.1016/j.oraloncology.2025.107461.
    PubMed     Abstract available


  310. EICKELSCHULTE S, Starus A, Murray DH, Keyser KA, et al
    Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
    Oral Oncol. 2025;167:107445.
    PubMed     Abstract available


  311. RAJATHIRAJAN SD
    Commentary on, "Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging".
    Oral Oncol. 2025;167:107453.
    PubMed    


  312. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
    Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact: Running title: Massive nasal bleeding in NPC.
    Oral Oncol. 2025;167:107456.
    PubMed     Abstract available


  313. DAUNGSUPAWONG H, Wiwanitkit V
    Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: Comment.
    Oral Oncol. 2025;167:107454.
    PubMed    


  314. SAMUEL CHAN SW, Amer Al Maqrashi ZA, Kim DH, Choi D, et al
    Induction chemotherapy and immunotherapy followed by chemo-radiotherapy in incurable advanced head and neck squamous cell carcinoma: A case-series.
    Oral Oncol. 2025;167:107439.
    PubMed    


  315. NGO DQ, Truong DS, Le DT, Hoang TM, et al
    Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: surgical and oncological outcomes.
    Oral Oncol. 2025;167:107406.
    PubMed     Abstract available


  316. ARAUJO M, Bouassaly J, Farshadi F, Hier M, et al
    Current status of circulating tumor DNA and circulating cell alterations in HPV-associated head and neck cancer.
    Oral Oncol. 2025;167:107417.
    PubMed     Abstract available


  317. KAMEL S, Humbert-Vidan L, Kaffey Z, Mirbahaeddin S, et al
    Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors.
    Oral Oncol. 2025;167:107337.
    PubMed     Abstract available


  318. MAK CH, Cao LM, Luo HY, Zhou K, et al
    Postoperative complications of neck dissection for head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Oral Oncol. 2025;167:107430.
    PubMed     Abstract available


  319. YANG X, Li R
    Reconsidering the prognostic value of HRQOL in head and neck cancer.
    Oral Oncol. 2025;167:107421.
    PubMed    


  320. YAN Y, Wang Z, Sun Y
    Comment on: Margins do not impact recurrence and survival in advanced laryngeal cancer-A retrospective cohort analysis.
    Oral Oncol. 2025;167:107427.
    PubMed    


  321. LIANG YJ, Luo MJ, Wen DX, Wang P, et al
    Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging.
    Oral Oncol. 2025;167:107404.
    PubMed     Abstract available


  322. KIM MJ, Koo BS, Cho KJ, Lee SH, et al
    Health-related quality-of-life assessment in patients with oropharyngeal cancer: A comparison of EQ-5D-5L and EORTC instruments.
    Oral Oncol. 2025;165:107342.
    PubMed     Abstract available


  323. GARSET-ZAMANI M, Makouei F, Agander TK, Lelkaitis G, et al
    Feasibility of 3D ultrasound for intraoperative tumor margin assessment in transoral robotic surgery for oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;165:107330.
    PubMed     Abstract available


  324. KUMARI S, Mishra S, Ali W, Singh US, et al
    Implication of circulating miRNAs as potential diagnostic biomarker in oropharyngeal squamous cell Carcinoma: Association with Human Papilloma Virus.
    Oral Oncol. 2025;165:107305.
    PubMed     Abstract available


  325. JANG HB, Lee DH, Lim SC
    Treatment outcomes of sinonasal adenoid cystic carcinoma: a single-center experience.
    Oral Oncol. 2025;165:107317.
    PubMed     Abstract available


  326. CHELVARAJAH RC, Liu Y, Su J, Abdalaty AH, et al
    Factors associated with detection of oligometastatic recurrence and outcome following definitive (Chemo)radiotherapy for oropharyngeal carcinoma.
    Oral Oncol. 2025;165:107310.
    PubMed     Abstract available


    May 2025
  327. HINTZE JM, Cleere E, Soo A, Timon C, et al
    Margins do not impact recurrence and survival in advanced laryngeal cancer - A retrospective cohort analysis.
    Oral Oncol. 2025;167:107402.
    PubMed     Abstract available


  328. BAIJU DC, Ravi J, Sarma M, Sureshan M, et al
    Detection of hotspot mutations in oral cancer through Ion AmpliSeq cancer hotspot panel v.2.0: A circulating DNA fragmentomics approach in the Northeast Indian population.
    Oral Oncol. 2025;166:107387.
    PubMed     Abstract available


  329. JEYARAJ G
    Commentary on, "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
    Oral Oncol. 2025;166:107401.
    PubMed    


  330. LIU X, Xue S
    Comment on: Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2025;166:107368.
    PubMed    


  331. VERDONCK-DE LEEUW IM, Lissenberg-Witte BI, de Bree R, Buffart LM, et al
    The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study.
    Oral Oncol. 2025;166:107367.
    PubMed     Abstract available


  332. OLSON B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, et al
    Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;166:107308.
    PubMed     Abstract available


  333. TONSBEEK AM, van der Lely JN, Bulstra L, Venema J, et al
    Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction.
    Oral Oncol. 2025;166:107363.
    PubMed     Abstract available


  334. MALI SB
    Corrigendum to "Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer" [Oral Oncol. 51 (2015) 565-569].
    Oral Oncol. 2025 May 10:107357. doi: 10.1016/j.oraloncology.2025.107357.
    PubMed    


  335. MALI SB
    Corrigendum to "RNA interference in oral cancer" [Oral Oncol. 51 (2015) e2-e3].
    Oral Oncol. 2025 May 9:107358. doi: 10.1016/j.oraloncology.2025.107358.
    PubMed    


  336. SHAIKH N, Pandey M, Manna S, Gawde J, et al
    Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy.
    Oral Oncol. 2025;165:107346.
    PubMed     Abstract available


  337. COSTANTINO A, Haughey BH, Alamoudi U, Magnuson JS, et al
    Prognostic significance of distant metastasis site at diagnosis in HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107361.
    PubMed     Abstract available


  338. ONAGA R, Enokida T, Kuno H, Hiyama T, et al
    Significance of imaging-detected extranodal extension in locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy followed by chemoradiotherapy.
    Oral Oncol. 2025;165:107351.
    PubMed     Abstract available


  339. ZHU X, Xu H, Zhao Y, Diao W, et al
    Single-cell transcriptomics reveal the effects of chemoimmunotherapy on hypopharyngeal cancer and its tumor microenvironment.
    Oral Oncol. 2025;165:107347.
    PubMed     Abstract available


  340. PEI Y, Yang Z, Mao Y, Chen X, et al
    Evolving dynamics in clinical trials for oral cancer: Trends, treatment modalities, and future directions.
    Oral Oncol. 2025;165:107333.
    PubMed     Abstract available


  341. XIAO X, Liu T, Lu M, Song Z, et al
    Comment on the role of lymph node level ratio in predicting prognosis of pN1 head and neck squamous cell carcinoma.
    Oral Oncol. 2025;165:107344.
    PubMed    


  342. CHENNAREDDY S, Chen S, Levinson C, Genden EM, et al
    Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review.
    Oral Oncol. 2025;164:107262.
    PubMed     Abstract available


  343. MARCHI F, Del Bon F, Chu F, Sampieri C, et al
    Refining prognostic subcategories in intermediate-advanced glottic cancer: A multicentric study on 637 patients treated by transoral laser microsurgery.
    Oral Oncol. 2025;164:107264.
    PubMed     Abstract available


  344. CANALI L, Russo E, Pangallo S, Bussu F, et al
    Regional disease control in nasal vestibule squamous cell carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2025;164:107270.
    PubMed     Abstract available


  345. MOTTA G, Magno C, Castagna L, De Berardinis T, et al
    Endoscope-assisted trans-oral approach (EATA) to remove a rare pleomorphic adenoma of the nasopharynx.
    Oral Oncol. 2025;164:107260.
    PubMed     Abstract available


  346. BEDDOK A, Popovtzer A, Calugaru V, Fontaine M, et al
    Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107309.
    PubMed     Abstract available


    April 2025
  347. MALI SB
    Corrigendum to "Proteomics for oral cancer" [Oral Oncol. 50(11) (2014) e67].
    Oral Oncol. 2025 Apr 30:107338. doi: 10.1016/j.oraloncology.2025.107338.
    PubMed    


  348. CITRO S, Ghiani L, Doni M, Miccolo C, et al
    HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer.
    Oral Oncol. 2025;165:107307.
    PubMed     Abstract available


  349. SILVA CUNHA JL
    Comment on "Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma".
    Oral Oncol. 2025;165:107336.
    PubMed    


  350. AL FADEL AM, Jakobsen KK, Jensen LH, Carlander AF, et al
    The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;165:107311.
    PubMed     Abstract available


  351. ARDILA CM
    Enhancing the scope and impact of photobiomodulation research in head and neck cancer therapy.
    Oral Oncol. 2025;165:107303.
    PubMed    


  352. JEYARAJ G
    Commentary on, "Molecular features of T and N stage progression in laryngeal cancer.".
    Oral Oncol. 2025;165:107331.
    PubMed    


  353. BARCELONA MVN, Waldron J, Sullivan BO, Su J, et al
    Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy.
    Oral Oncol. 2025;165:107299.
    PubMed     Abstract available


  354. YAO CMKL, Hueniken K, Huang SH, Liu G, et al
    Development of a patient reported outcomes based machine learning model to predict recurrences in head and neck cancer.
    Oral Oncol. 2025;165:107304.
    PubMed     Abstract available


  355. JEYARA G
    Commentary on, "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.".
    Oral Oncol. 2025;165:107320.
    PubMed    


  356. ZHOU P, Zhu Y, Xu B, Jiang X, et al
    Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge.
    Oral Oncol. 2025;165:107316.
    PubMed     Abstract available


  357. COSTANTINO A, Sampieri C, Haughey BH, Alamoudi U, et al
    Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107312.
    PubMed     Abstract available


  358. KOSKENNIEMI AR, Huusko T, Routila J, Jalkanen S, et al
    Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;165:107287.
    PubMed     Abstract available


  359. JEYARAJ G
    Commentary on, "Effect of Enhanced Recovery After Radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial".
    Oral Oncol. 2025;165:107302.
    PubMed    


  360. LI N, Zeng PYF, Kim HAJ, Karimi A, et al
    Molecular features of T and N stage progression in laryngeal cancer.
    Oral Oncol. 2025;165:107283.
    PubMed     Abstract available


  361. BURGER AVM, Koot MA, van Balen DEM, Schaeffers AWMA, et al
    Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.
    Oral Oncol. 2025;164:107246.
    PubMed     Abstract available


  362. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].
    Oral Oncol. 2025 Apr 11:107292. doi: 10.1016/j.oraloncology.2025.107292.
    PubMed    


  363. MA J, Brooks C, Tasoulas J, Wind LS, et al
    Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2025;164:107293.
    PubMed    


  364. SLATER NN, Herberger L, Farsi S, Rogers AL, et al
    Assessing barriers to adjuvant therapy among patients with head and neck cancer in Arkansas.
    Oral Oncol. 2025;164:107290.
    PubMed     Abstract available


  365. XIAO J, You M, Song Y, Gao R, et al
    Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.
    Oral Oncol. 2025;164:107288.
    PubMed     Abstract available


  366. VIANNA CAMOLESI GC, Prado-Pena IB, Gomez-Caamano A, Victoria-Fernandez C, et al
    Photobiomodulation for the prevention of oral side effects secondary to head and neck cancer therapy: results of a randomised, single-blind clinical trial.
    Oral Oncol. 2025;164:107266.
    PubMed     Abstract available


  367. JEYARAJ G
    Commentary on, "Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort".
    Oral Oncol. 2025;164:107285.
    PubMed    


  368. ROSING F, Plath M, Proctor T, Hofler D, et al
    Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA.
    Oral Oncol. 2025;163:107225.
    PubMed     Abstract available


    March 2025
  369. LIN N, Zhou X, Wang Y, Zhou J, et al
    Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
    Oral Oncol. 2025;164:107269.
    PubMed     Abstract available


  370. JEYARAJ G
    Commentary on, "Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study".
    Oral Oncol. 2025;163:107256.
    PubMed    


  371. ARDILA CM, Yadalam PK
    AI-driven histopathologic insights in HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107261.
    PubMed    


  372. MATHEW JM, Busca I, Baskurt Z, Giuliani M, et al
    Changes in unmet needs after treatment for head and neck cancers - A prospective longitudinal cohort study.
    Oral Oncol. 2025;163:107250.
    PubMed     Abstract available


  373. DONG Z, Wang GY, Qin GJ, Dai DY, et al
    Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study.
    Oral Oncol. 2025;163:107223.
    PubMed     Abstract available


  374. LORENZ FJ, Kharouta M, Mahase SS, Goyal N, et al
    Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Oral Oncol. 2025;163:107251.
    PubMed     Abstract available


  375. PETRELLI F, Lorini L, Paderno A, Carioli D, et al
    Treatment of primary tumor in metastatic head and neck Carcinoma: A systematic review and Meta-Analysis.
    Oral Oncol. 2025;163:107248.
    PubMed     Abstract available


  376. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107207.
    PubMed     Abstract available


  377. GAZZINI L, Festa BM, Calabrese L
    Elective neck dissection: Are we bound to outdated concepts?
    Oral Oncol. 2025;163:107245.
    PubMed    


  378. WU WJ, An PG, Liu Q, Zhang ZQ, et al
    Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis.
    Oral Oncol. 2025;162:107218.
    PubMed     Abstract available


  379. YANG F, Peng W, Wei H, Li X, et al
    Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC.
    Oral Oncol. 2025;162:107187.
    PubMed     Abstract available


  380. YE Z, Li X, Xie F, Sun J, et al
    A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma.
    Oral Oncol. 2025;162:107185.
    PubMed     Abstract available


  381. CHARLTON A, Mughal Z, Sharin F, Sahota RB, et al
    Prevalence of synchronous bilateral/contralateral tonsil carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2025;162:107180.
    PubMed     Abstract available


  382. DE VETTE SPM, van Rijn-Dekker MI, Van den Bosch L, Keijzer K, et al
    Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort.
    Oral Oncol. 2025;163:107224.
    PubMed     Abstract available


  383. MIYAGUCHI J, Shiga K, Katagiri K, Saito D, et al
    Efficacy of boron neutron capture therapy (BNCT) for patients with oral cancer.
    Oral Oncol. 2025;163:107228.
    PubMed     Abstract available


    February 2025
  384. WICZUK-WICZEWSKA M, Bernaciak J, Nogal P, Bugaj A, et al
    Squamous cell carcinoma in the posterior larynx: A rare localization of supraglottic T1 laryngeal cancer. Case report.
    Oral Oncol. 2025;163:107227.
    PubMed     Abstract available


  385. JEYARAJ G
    Letter to the editor, "Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell carcinoma: A multicenter, open-label, single-arm, phase 1b study.".
    Oral Oncol. 2025;163:107231.
    PubMed    


  386. TINO RB, Roach MA, Fuentes GD, Agrawal A, et al
    Response to recent comments on "Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy".
    Oral Oncol. 2025;162:107220.
    PubMed    


  387. MEEKER BS MO, Katragadda A, Alsavaf MB, Birkenbeuel J, et al
    Dysphagia in head and neck cancer patients with evidence of esophageal dysmotility on manometry.
    Oral Oncol. 2025;162:107219.
    PubMed     Abstract available


  388. YANG H, Sun P, Wang Y, Wang X, et al
    Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study.
    Oral Oncol. 2025;162:107211.
    PubMed     Abstract available


  389. IQBAL MS, West N, Kovarik J, Jackson M, et al
    Effective, efficient palliative radiotherapy for advanced head and neck cancer: Real world data using 25 Gy in 5 fractions.
    Oral Oncol. 2025;162:107214.
    PubMed    


  390. KHAN A, Pillay M, Bipath R, Msimang M, et al
    Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
    Oral Oncol. 2025;162:107208.
    PubMed     Abstract available


  391. MO Y, Wei Y, Liang L, Wu T, et al
    Clinical significance of post-chemoradiotherapy 2-[(18)F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study.
    Oral Oncol. 2025;161:107160.
    PubMed     Abstract available


  392. LOUBIERES C, Baudouin R, Circiu M, Couineau F, et al
    Functional and oncological outcomes of transoral laser versus robotic surgery in supraglottic squamous cell carcinoma.
    Oral Oncol. 2025;161:107178.
    PubMed     Abstract available


  393. PERSHAD AR, Ferraro T, Shaver TB, Lee E, et al
    Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer.
    Oral Oncol. 2025;161:107139.
    PubMed     Abstract available


  394. FENG ZK, Wu WB, Zou RC, Zhang JZ, et al
    Postradiotherapy nasopharyngeal necrosis with granulation mass: Insights from a multicentre study.
    Oral Oncol. 2025;161:107170.
    PubMed     Abstract available


  395. LYU SI, Fretter C, Eckel HNC, Knipper K, et al
    High expression of H2AX/gamma-H2AX is associated with distinct biological pathway alterations and shorter survival in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;161:107171.
    PubMed     Abstract available


  396. KWON JJ, Milner TD, Kurten C, Pang EH, et al
    Towards transcervical ultrasound-guided transoral robotic surgery.
    Oral Oncol. 2025;161:107167.
    PubMed     Abstract available


  397. SUCHAN M, Wuerdemann N, Wagner S, Langer C, et al
    Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2025;162:107209.
    PubMed     Abstract available


    January 2025
  398. WENGER TA, Gao J, Nurimba M, Phung PG, et al
    Palliative care utilization among head and neck cancer patients: A population-based analysis.
    Oral Oncol. 2025;162:107205.
    PubMed     Abstract available


  399. CHEN L, Fang R, Cai Z, Huang B, et al
    CD271(high) cancer stem cells regulate macrophage polarization in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;162:107181.
    PubMed     Abstract available


  400. YIN Z, Zhao H, Zhu C, Fang J, et al
    Comment on: Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2025;161:107195.
    PubMed    


  401. JIANG H, Zhou L, Zhao T, Zou G, et al
    Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report.
    Oral Oncol. 2025;161:107192.
    PubMed    


  402. JIANG H, Zhou L, Zou G, Zhang H, et al
    Synchronous papillary and medullary thyroid carcinoma with distinct genetic mutations: A case report.
    Oral Oncol. 2025;161:107191.
    PubMed    


  403. LI MH, Hu YJ, Shan HM, Gao XL, et al
    The role of lymph node level ratio in predicting prognosis and the benefits of postoperative radiotherapy in patients with pathological N1 stage head and neck squamous cell carcinoma.
    Oral Oncol. 2025;161:107193.
    PubMed     Abstract available


  404. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
    Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;161:107179.
    PubMed     Abstract available


  405. TOPKAN E, Somay E, Selek U
    Commentary on "Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF".
    Oral Oncol. 2025;161:107175.
    PubMed    


  406. SENYUREK S, Durankus NK, Selek U, Topkan E, et al
    Comment on "The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2025;161:107177.
    PubMed    


  407. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
    From infection to immortality: The role of HPV and telomerase in head and neck cancer.
    Oral Oncol. 2025;161:107169.
    PubMed     Abstract available


  408. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.
    Oral Oncol. 2025;161:107146.
    PubMed     Abstract available


  409. XU S, He J, Liu Z, Pei Y, et al
    Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;161:107161.
    PubMed     Abstract available


    December 2024
  410. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
    The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
    Oral Oncol. 2024;161:107148.
    PubMed     Abstract available


  411. LIU Y, Fu N, Liu H, Su S, et al
    Corrigendum to "Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations" [160 (2025) 107120/Article:OO_107120].
    Oral Oncol. 2024 Dec 30:107135. doi: 10.1016/j.oraloncology.2024.107135.
    PubMed    


  412. DIETRICH N, Watson E, Tadic T, Martino R, et al
    Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
    Oral Oncol. 2024;161:107132.
    PubMed     Abstract available


  413. FANG Q, Yuan J, Zhang X, Dai L, et al
    Omitting elective neck dissection in cT1/2N0 oral squamous cell carcinoma with sentinel lymph node metastasis: A prospective study.
    Oral Oncol. 2024;161:107149.
    PubMed     Abstract available


  414. PRICE JM, Garcez K, Hughes C, Lee LW, et al
    The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2024;161:107138.
    PubMed     Abstract available


  415. STRUCKMEIER AK, Gosau M, Smeets R
    Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA.
    Oral Oncol. 2024;161:107145.
    PubMed     Abstract available


  416. MEGWALU UC, Ma Y, Divi V
    Association of race and ethnicity with quality of care among head and neck cancer patients in California.
    Oral Oncol. 2024;161:107144.
    PubMed     Abstract available


  417. PACE GM, Costantino A, De Virgilio A
    Comment on "Surgical, functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal cancers: A systematic review".
    Oral Oncol. 2024;161:107142.
    PubMed    


  418. YU ST, Huang D, Xiong C, Xie R, et al
    Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports.
    Oral Oncol. 2024;161:107140.
    PubMed     Abstract available


  419. ALMEIDA ND, Yu H, Iovoli AJ, Fang M, et al
    Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months.
    Oral Oncol. 2024;160:107136.
    PubMed     Abstract available


  420. DA MOTA SANTANA LA, Dos Santos Barreto M, Santos GA, Gopalsamy RG, et al
    Comment on "Time to treatment for head and neck cancer patients decreased during the early phase of the COVID-19 pandemic".
    Oral Oncol. 2024;160:107134.
    PubMed    


  421. PRACHA SH, Shrestha S, Ryan N, Upadhaya P, et al
    Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;160:107126.
    PubMed     Abstract available


  422. LI H, Lou L, Du J, Li M, et al
    Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;160:107129.
    PubMed     Abstract available


  423. SANKAR GANESH P, Naseef Pathoor N, Kanna Gopal R
    Letter to the editor regarding, "Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2024;159:107091.
    PubMed     Abstract available


  424. BALAJI H, Aithal VU, Varghese JJ, Devaraja K, et al
    Agreement between patient-reported and clinician-rated speech and swallowing outcomes - Understanding the trend in post-operative oral cavity cancer patients.
    Oral Oncol. 2024;159:107068.
    PubMed     Abstract available


  425. BALAGURU L, Hanubal KS, Galochkina Z, Lee JH, et al
    Surgical and functional outcomes after salvage oropharyngectomy.
    Oral Oncol. 2024;159:107050.
    PubMed     Abstract available


  426. KORIC A, Chang CP, Hu S, Snyder J, et al
    Oral health-related quality of life among oropharyngeal cancer survivors.
    Oral Oncol. 2024;159:107062.
    PubMed     Abstract available


  427. BOZKURT G, Turri Zanoni M, Ferrari M, Ioppi A, et al
    Salvage surgery in nasopharyngeal Cancer: Unraveling the efficacy of transnasal endoscopic nasopharyngectomy for advanced stage recurrent tumors.
    Oral Oncol. 2024;159:107048.
    PubMed     Abstract available


  428. DANIELS KE, Awad DR, Liu SX, Mocharnuk J, et al
    Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107031.
    PubMed     Abstract available


  429. GREEN L, McDowell L, Ip F, Tapia M, et al
    Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107032.
    PubMed     Abstract available


  430. LU YT, Lin CW, Su SC, Ho YT, et al
    L48H37, a curcumin analog, suppresses matrix metalloproteinase-9 expression and activity to hamper nasopharyngeal cancer cell migration.
    Oral Oncol. 2024;159:107038.
    PubMed     Abstract available


  431. STAIBANO P, Au M, Xie M, Gupta MK, et al
    Return to work and self-reported swallowing following transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma: A retrospective cohort study.
    Oral Oncol. 2024;159:107033.
    PubMed     Abstract available


  432. MORTAJA S, Chiumenti FA, Kalaskar DM, Dwivedi RC, et al
    Surgical complications and functional outcomes of 3191 jejunal free flaps used for reconstruction of circumferential defects following head and neck cancer resections: A systematic review.
    Oral Oncol. 2024;160:107130.
    PubMed     Abstract available


    November 2024
  433. MARRET G, Lamy C, Vacher S, Cabel L, et al
    Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA.
    Oral Oncol. 2024;160:107111.
    PubMed     Abstract available


  434. JEYARAJ G
    Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
    Oral Oncol. 2024;160:107092.
    PubMed    


  435. LIU Y, Fu N, Liu H, Su S, et al
    Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2024;160:107120.
    PubMed     Abstract available


  436. YAN C, Wang R, Zhang C, Lin G, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF.
    Oral Oncol. 2024;160:107119.
    PubMed     Abstract available


  437. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
    Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
    Oral Oncol. 2024;159:107107.
    PubMed     Abstract available


  438. LI S, Zhao T, Liu N, Li Y, et al
    Global research on oral cancer: A bibliometric analysis based on 82 highly cited publications from 2014 to 2024.
    Oral Oncol. 2024;159:107094.
    PubMed     Abstract available


  439. YANG B, Dai X, Li Z, Wu Z, et al
    Noninvasive surface-enhanced Raman spectroscopy outperforms combined positive score in predicting sensitivity to neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107105.
    PubMed     Abstract available


  440. RENGASAMY G, Priya Veeraraghavan V
    Using salivary DNA methylation to predict aging, cell changes, and protein levels for assessing oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107086.
    PubMed    


  441. LEE YC, Hsin LJ, Lin WN, Fang TJ, et al
    Robot-assisted versus conventional neck dissection in head and neck cancers: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107101.
    PubMed     Abstract available


  442. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
    Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
    Oral Oncol. 2024;159:107089.
    PubMed     Abstract available


  443. LENNON SILVA CUNHA J
    In reply to "Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study".
    Oral Oncol. 2024;159:107096.
    PubMed    


  444. TOPKAN E, Somay E, Ozturk D, Selek U, et al
    Commentary on "Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions".
    Oral Oncol. 2024;159:107099.
    PubMed    


  445. SHANG K, Li T, Chen Y, Luo X, et al
    Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial.
    Oral Oncol. 2024;159:107087.
    PubMed     Abstract available


  446. COSTANTINO A, Haughey B, Alamoudi U, Magnuson JS, et al
    Challenges in treating oropharyngeal cancer in the elderly: The role of transoral surgery.
    Oral Oncol. 2024;158:106996.
    PubMed    


  447. SOLARZ P, Mackiewicz-Nartowicz H, Sinkiewicz A, Burduk P, et al
    Results of CO2 laser surgery in laryngeal papillomatosis.
    Oral Oncol. 2024;158:107004.
    PubMed     Abstract available


  448. ASHIQUE S, Houshyari M, Islam A, Pal R, et al
    The role of microbiota in nasopharyngeal cancer: Where do we stand?
    Oral Oncol. 2024;158:106982.
    PubMed     Abstract available


  449. DE SENA COSTA DE OLIVEIRA D, Cunha JLS
    Comment on: Salivary DNA methylation derived estimates of biological aging, cellular frequency, and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107097.
    PubMed    


  450. HIMANI
    Letter to the editor: Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107093.
    PubMed    


    October 2024
  451. MUTHAMIZH S, Balachandran S, Dilipan E
    Opinion on "Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107095.
    PubMed    


  452. LEHYANTI J, Even C, Fessart E, Wagner-Ballon C, et al
    Management of oligometastatic head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2024;159:107085.
    PubMed     Abstract available


  453. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
    Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2024;159:107082.
    PubMed     Abstract available


  454. KARAMCHANDANI S, Sahovaler A, Crosbie-Jones E, McGurk M, et al
    Incidence and predictive factors for positive non-sentinel lymph nodes in completion neck dissection following a positive sentinel node biopsy in early oral cancer.
    Oral Oncol. 2024;159:107081.
    PubMed    


  455. LI D, Lopez A, Shrivastava N, Chan W, et al
    Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics.
    Oral Oncol. 2024;159:107069.
    PubMed     Abstract available


  456. WU WB, Xia L, Feng ZK, Liang JL, et al
    Characteristics and treatment of epistaxis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107071.
    PubMed     Abstract available


  457. ZANG Y, Lu Y, Yu J, Dong Q, et al
    FOXP3 inhibits proliferation and migration by competitively inhibiting YAP1 in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107066.
    PubMed     Abstract available


  458. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
    Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
    Oral Oncol. 2024;159:107073.
    PubMed     Abstract available


  459. LIU C, Zhao H, Lu Y, Xia Y, et al
    Nomograms to predict occult contralateral central lymph node metastases in unilateral papillary thyroid carcinoma with ipsilateral clinical lymph node metastasis.
    Oral Oncol. 2024;159:107051.
    PubMed     Abstract available


  460. SONG Y, Zhang Y, Bai Y, Wang T, et al
    Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study.
    Oral Oncol. 2024;159:107067.
    PubMed     Abstract available


  461. AWEEDA M, Richard K, Arnaud EH, Divi V, et al
    Factors influencing lymph node yield in head and neck squamous cell carcinoma: A scoping review.
    Oral Oncol. 2024;159:107070.
    PubMed     Abstract available


  462. HE SQ, Liu GY, Yu YH, Wang L, et al
    Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.
    Oral Oncol. 2024;159:107074.
    PubMed     Abstract available


  463. LEE RH, Evans C, Alqasieer Y, Knott PD, et al
    Bite me: Can active biting during trismus therapy improve mouth opening in head and neck cancer patients?
    Oral Oncol. 2024;159:107064.
    PubMed    


  464. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
    Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107057.
    PubMed     Abstract available


  465. TANG WZ, Xu WZ, Liu TH
    Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107065.
    PubMed    


  466. YACOUB I, Qian JY, Nashed K, Youssef M, et al
    Radiation techniques and advancements in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107060.
    PubMed    


  467. GAUDIOSO P, Contro G, Taboni S, Costantino P, et al
    Intraoperative surgical navigation as a precision medicine tool in sinonasal and craniofacial oncologic surgery.
    Oral Oncol. 2024;157:106979.
    PubMed     Abstract available


  468. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
    Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2024;159:107061.
    PubMed     Abstract available


  469. AKASHANAND, Zahiruddin QS, Jena D, Ballal S, et al
    Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107063.
    PubMed     Abstract available


    September 2024
  470. LECHIEN JR
    Surgical, Functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;159:107047.
    PubMed     Abstract available


  471. KEEFE K, McCrary HC, Wei M, Mark B, et al
    Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study.
    Oral Oncol. 2024;159:107041.
    PubMed     Abstract available


  472. DHARSHINI RAJATHIRAJAN S
    Commentary on "Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients".
    Oral Oncol. 2024;159:107053.
    PubMed    


  473. LYU W, Gong J, Zhu L, Xu T, et al
    MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2024;159:107049.
    PubMed     Abstract available


  474. PRITHVIRAJ
    Comment on "Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer".
    Oral Oncol. 2024;159:107054.
    PubMed    


  475. DINESHKUMAR R
    Letter to the editor: Risk factors associated with ototoxicity in long-term survivors of nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107052.
    PubMed    


  476. VALCENKO A, Zwick A, Schneider L, Linxweiler M, et al
    The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype.
    Oral Oncol. 2024;159:107042.
    PubMed     Abstract available


  477. MIN Y, Liu X, Wei Z, Song G, et al
    Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2024;159:107028.
    PubMed     Abstract available


  478. RENGASAMY G, Priya Veeraraghavan V
    Comment on "The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-) radiotherapy".
    Oral Oncol. 2024;159:107035.
    PubMed    


  479. DHARSHINI RAJATHIRAJAN S
    Commentary on "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.".
    Oral Oncol. 2024;159:107037.
    PubMed    


  480. DHARSHINI RAJATHIRAJAN S
    Commentary on "Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients".
    Oral Oncol. 2024;159:107036.
    PubMed    


  481. VERSCHOOR CP, Santi SA, Singh R, Tharmalingam S, et al
    Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107030.
    PubMed     Abstract available


  482. PAKA LUBAMBA G, Hua Y, Bao M, Zhang G, et al
    Variant of internal jugular vein reconstruction in bilateral radical neck dissection.
    Oral Oncol. 2024;159:107015.
    PubMed     Abstract available


  483. WANG A, Xia H, Li J, Diao P, et al
    Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107016.
    PubMed     Abstract available


  484. PRITHVIRAJ T
    Commentary on "Tumor Habitat-Based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107018.
    PubMed    


  485. XIAOYU J, Baihong P, Yaozhen L, Shen C, et al
    Preoperative protective stenting of the carotid artery in severe complex head and neck cancer resection.
    Oral Oncol. 2024;158:107012.
    PubMed     Abstract available


  486. PAYNE K, Suriyanarayanan H, Brooks J, Mehanna H, et al
    Exploring the impact of intra-tumoural heterogeneity on liquid biopsy cell-free DNA methylation and copy number in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107011.
    PubMed     Abstract available


  487. ZHANG X, Zheng W, Huang S, Li H, et al
    Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models.
    Oral Oncol. 2024;158:107000.
    PubMed     Abstract available


  488. CHEN J, Cheng H, Liang Y, Lin J, et al
    The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads.
    Oral Oncol. 2024;156:106938.
    PubMed     Abstract available


    August 2024
  489. LECHIEN JR, Hans S
    Survival, Surgical, and functional outcomes of transoral laser microsurgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;158:107009.
    PubMed     Abstract available


  490. ZHAO J, Ruan X, Wei S, Zheng X, et al
    The first report of bilateral parapharyngeal lymph node metastasis from papillary thyroid carcinoma: A case report.
    Oral Oncol. 2024;158:107006.
    PubMed    


  491. YIN WJ, Mao W, Yang F, Wang MY, et al
    Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions.
    Oral Oncol. 2024;158:107001.
    PubMed     Abstract available


  492. GE Y, Liu H, Huang W, Zhu H, et al
    Immunoinhibitory effects of hypoxia-driven reprogramming of EGR1(hi) and EGR3 positive B cells in the nasopharyngeal carcinoma microenvironment.
    Oral Oncol. 2024;158:106999.
    PubMed     Abstract available


  493. T P
    Commentary on "Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/mHNSCC)".
    Oral Oncol. 2024;158:107010.
    PubMed    


  494. ZHOU X, Shao T, Jia H, Hou L, et al
    Current state, challenges, and future perspective of adaptive radiotherapy: A narrative review of nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:107008.
    PubMed     Abstract available


  495. PRASAD M
    DNA Methylation Mediated Epigenetic Silencing of PD-1 and PD-L1: Therapeutic Implications in Oral Cancer.
    Oral Oncol. 2024 Aug 23:106995. doi: 10.1016/j.oraloncology.2024.106995.
    PubMed    


  496. KNAP RABJERG H, Grau Eriksen J, Soby S
    Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107003.
    PubMed    


  497. DU F, Shao K, Yang Y, Bai X, et al
    Comparative dosimetric analysis of normal brain tissue in patients with Nasopharyngeal carcinoma at different stages after radiation therapy.
    Oral Oncol. 2024;158:106998.
    PubMed     Abstract available


  498. ALSHEIKH S, Su J, O'Sullivan B, Ringash J, et al
    The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy.
    Oral Oncol. 2024;158:107007.
    PubMed     Abstract available


  499. SUN L, Cohen RB, Dimitrios Colevas A
    Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
    Oral Oncol. 2024;158:106997.
    PubMed     Abstract available


  500. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
    Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
    Oral Oncol. 2024;158:107002.
    PubMed     Abstract available


  501. YUAN J, Wu M, Qiu L, Xu W, et al
    Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:106980.
    PubMed     Abstract available


  502. YANG R, Li R, Niu X, Zhao Y, et al
    Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.
    Oral Oncol. 2024;158:106981.
    PubMed     Abstract available


  503. HUSSEIN NI, Molina AH, Sunga GM, Amit M, et al
    Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;158:106986.
    PubMed     Abstract available


  504. PAN GS, Sun XM, Kong FF, Wang JZ, et al
    Delta magnetic resonance imaging radiomics features?based nomogram predicts long?term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106987.
    PubMed     Abstract available


  505. QIN G, Liao X, Zhang B, Su Y, et al
    An individualized immune prognostic signature in nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106985.
    PubMed     Abstract available


  506. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
    HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
    Oral Oncol. 2024;157:106983.
    PubMed     Abstract available


  507. SHIMIZU H, Kodaira T, Kiyota N, Hayashi R, et al
    Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
    Oral Oncol. 2024;157:106976.
    PubMed     Abstract available


  508. SANKAR S
    Letter to editor regarding "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression".
    Oral Oncol. 2024;157:106977.
    PubMed    


  509. SCHAEFFERS AWMA, Scholten HA, van Beers MA, Meussen BW, et al
    The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;157:106978.
    PubMed     Abstract available


    July 2024
  510. MCDOWELL L, Gough K, White I, Corry J, et al
    Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer - A narrative review.
    Oral Oncol. 2024;157:106975.
    PubMed     Abstract available


  511. DAS S, Ghosh Laskar S, V Kane S, D'Cruz AK, et al
    Adjuvant therapy for intermediate risk factors in oral cancer: Can we reach a consensus?
    Oral Oncol. 2024;157:106972.
    PubMed     Abstract available


  512. JEYARAJ G
    Letter to the editor, "Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the head and neck Cancer Registry of Japan.".
    Oral Oncol. 2024;157:106974.
    PubMed    


  513. JEYARAJ G
    Letter to the editor, "Mutation detection in saliva from oral cancer patients".
    Oral Oncol. 2024;157:106929.
    PubMed    


  514. GANESH PS, Pathoor NN, Gopal RK
    Letter to the editor regarding "Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;157:106954.
    PubMed     Abstract available


  515. LORINI L, Zigliani G, Morbini P, Salviato E, et al
    Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study).
    Oral Oncol. 2024;157:106950.
    PubMed     Abstract available


  516. JEYACHANDRAN S
    Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
    Oral Oncol. 2024;157:106973.
    PubMed     Abstract available


  517. SURESH S
    Comment on: An algorithm for standardization of tumor infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;157:106959.
    PubMed    


  518. WEN YF, Huang WJ, Chen XL, Cai HT, et al
    Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients.
    Oral Oncol. 2024;157:106963.
    PubMed     Abstract available


  519. ICHISAKA T, Sano D, Kijima N, Kawakita D, et al
    Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the Head and Neck Cancer Registry of Japan.
    Oral Oncol. 2024;157:106942.
    PubMed     Abstract available


  520. TINO R, Roach MA, Fuentes GD, Agrawal A, et al
    Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2024;157:106944.
    PubMed     Abstract available


  521. LIM CY, Ng GWY, Goh CK, Lee MKC, et al
    Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.
    Oral Oncol. 2024;157:106941.
    PubMed     Abstract available


  522. SHANMUGAM G
    Letter to the editor, "The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.".
    Oral Oncol. 2024;157:106951.
    PubMed    


  523. MEIVELU MOOVENDHAN
    "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)".
    Oral Oncol. 2024;157:106940.
    PubMed    


  524. ZENGA J, Himburg HA, Wong SJ, Kearl T, et al
    In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations.
    Oral Oncol. 2024 Jul 14:106947. doi: 10.1016/j.oraloncology.2024.106947.
    PubMed    


  525. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma".
    Oral Oncol. 2024;156:106948.
    PubMed    


  526. SHANMUGAM G
    Commentary on, "Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.".
    Oral Oncol. 2024;156:106952.
    PubMed    


  527. PIYARATHNE NS, Liyanage SN, Rasnayaka RMSGK, Hettiarachchi PVKS, et al
    A comprehensive dataset of annotated oral cavity images for diagnosis of oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;156:106946.
    PubMed     Abstract available


  528. MAHDI AGM
    Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
    Oral Oncol. 2024;156:106939.
    PubMed     Abstract available


  529. SHANMUGAM G
    Letter to the editor, "Letter to the editor, "Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.".
    Oral Oncol. 2024;156:106935.
    PubMed    


  530. ARUMUGANAINAR D, Sekaran S
    Correspondence on "Global burdens of nasopharyngeal carcinoma in children and young adults: Trends and predictions to 2040".
    Oral Oncol. 2024;156:106933.
    PubMed    


  531. GU LW, Zhang X, Zhang J, Xiao BB, et al
    The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2024;156:106928.
    PubMed     Abstract available


  532. SURESH S
    Commentary on 'Mutation detection in saliva from oral cancer patients'.
    Oral Oncol. 2024;156:106937.
    PubMed    


  533. KASIRAJAN H, Rengasamy G, Priya Veeraraghavan V
    Comment on the "Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module".
    Oral Oncol. 2024;156:106934.
    PubMed    


  534. KANNAN R
    Comments on: Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
    Oral Oncol. 2024;156:106936.
    PubMed    


  535. DAUNGSUPAWONG H, Wiwanitkit V
    Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
    Oral Oncol. 2024;156:106930.
    PubMed    


  536. LIOKATIS P, Liokati I, Obermeier K, Smolka W, et al
    Prognostic role of lymph node micrometastasis in oral and oropharyngeal cancer: A systematic review.
    Oral Oncol. 2024;154:106808.
    PubMed     Abstract available


  537. CHEN AM
    Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
    Oral Oncol. 2024;154:106850.
    PubMed     Abstract available


  538. SATHISHKUMAR K
    Letter to the editor "risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial ".
    Oral Oncol. 2024;156:106931.
    PubMed    


  539. HARIDEVAMUTHU B
    Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
    Oral Oncol. 2024;156:106913.
    PubMed    


    June 2024
  540. BENJAMIN WJ, Feng AL, Heft Neal M, Bellile E, et al
    Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer.
    Oral Oncol. 2024;156:106917.
    PubMed     Abstract available


  541. ZHAO X, Zhou Y, Peng G, Wen L, et al
    Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2024;156:106918.
    PubMed     Abstract available


  542. SARAVANAN M, Singh Carmelin D, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;156:106911.
    PubMed    


  543. POONGAVANAM SS, Behera A, Dharmalingam Jothinathan MK
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;156:106912.
    PubMed    


  544. JEYARAJ G
    Letter to the editor, "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer".
    Oral Oncol. 2024;156:106906.
    PubMed    


  545. DONG S, Bei W, Lin L, Jiang Y, et al
    Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.
    Oral Oncol. 2024;156:106908.
    PubMed     Abstract available


  546. JEYARAJ G
    Transformative impact of 3D-Printed implants and Virtual surgical planning in oral cancer reconstruction.
    Oral Oncol. 2024;156:106896.
    PubMed    


  547. SHANMUGAM G
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.".
    Oral Oncol. 2024;156:106915.
    PubMed    


  548. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
    Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;156:106894.
    PubMed     Abstract available


  549. HARIDEVAMUTHU B
    Letter to the Editor: "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral Cancer".
    Oral Oncol. 2024;155:106902.
    PubMed    


  550. MEIVELU MOOVENDHAN
    Letter to the editor, "Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2024;155:106903.
    PubMed    


  551. PRASAD M, Sekar R, Murugan R
    Letter to editor on "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;155:106899.
    PubMed    


  552. SELVI POONGAVANAM S, Behera A, Kumar Dharmalingam Jothinathan M
    Letter to the Editor, "The predictive role of PD-L1 in head and neck Cancer: A systematic review and Meta-Analysis".
    Oral Oncol. 2024;155:106904.
    PubMed    


  553. TOPKAN E, Somay E, Bascil S, Selek U, et al
    Comment on prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;155:106898.
    PubMed    


  554. HARIDEVAMUTHU B
    Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
    Oral Oncol. 2024;155:106895.
    PubMed    


  555. LEI S, Chen L, Ji P, Li K, et al
    Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040.
    Oral Oncol. 2024;155:106891.
    PubMed     Abstract available


  556. DA MOTA SANTANA LA, Simoes JMD, Santos GA, Gopalsamy RG, et al
    Comment on "Association between COVID 19 exposure and expression of malignant pathological features in oral cancer: A retrospective cohort study".
    Oral Oncol. 2024;155:106877.
    PubMed    


  557. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
    Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
    Oral Oncol. 2024;155:106874.
    PubMed     Abstract available


  558. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    Corrigendum to "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group" [Oral Oncol. 152C (2024) 106744].
    Oral Oncol. 2024 Jun 8:106887. doi: 10.1016/j.oraloncology.2024.106887.
    PubMed    


  559. PRASAD M, Murugan R
    Comment on "The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis".
    Oral Oncol. 2024;155:106890.
    PubMed    


  560. TASOULAS J, Adams GJ, Schrank TP, Agala CB, et al
    Time to treatment for head and neck cancer patients decreased during the early phase of the Covid-19 pandemic.
    Oral Oncol. 2024;155:106879.
    PubMed    


  561. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? A multi-institutional study on 366 patients from the ARYFIX collaborative group".
    Oral Oncol. 2024;155:106878.
    PubMed    


  562. BABU S, Krishnan M
    Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
    Oral Oncol. 2024;153:106824.
    PubMed    


  563. PACE GM, Costantino A, Festa BM, Spriano G, et al
    Oropharyngeal squamous cell carcinoma: Treatment (de-) intensification?
    Oral Oncol. 2024;153:106299.
    PubMed    


  564. LU HA, Wang YM, Chih Chen W, Wu CN, et al
    Post-irradiation dysbiosis in patients with nasopharyngeal carcinoma having received radiotherapy - A pilot study.
    Oral Oncol. 2024;154:106864.
    PubMed     Abstract available


  565. KRC R, Mendes W, Molitoris J, Ferris M, et al
    Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.
    Oral Oncol. 2024;154:106875.
    PubMed     Abstract available


    May 2024
  566. XU W, Qiu L, Li F, Fei Y, et al
    Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;154:106865.
    PubMed     Abstract available


  567. IMAMURA Y, Kiyota N, Tahara M, Kodaira T, et al
    Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
    Oral Oncol. 2024;154:106868.
    PubMed     Abstract available


  568. PARK R, Li J, Slebos RJC, Chaudhary R, et al
    Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;154:106866.
    PubMed     Abstract available


  569. SARAVANAN M, Carmelin DS, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;154:106858.
    PubMed    


  570. HESHAM A, David Kim D, Alshamrani Y, AlOtaibi F, et al
    The efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy in recurrent head and neck squamous cell carcinoma. Report of a case and review of the literature.
    Oral Oncol. 2024;154:106863.
    PubMed    


  571. ABBACI M, Villard A, Auperin A, Asmandar S, et al
    Ultra-fast confocal fluorescence microscopy for neck lymph node imaging in head and neck cancer.
    Oral Oncol. 2024;154:106862.
    PubMed     Abstract available


  572. YAO Y, Ouyang Q, Wang S, Li K, et al
    Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
    Oral Oncol. 2024;154:106867.
    PubMed     Abstract available


  573. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    In response to the reply on 'Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes'.
    Oral Oncol. 2024;154:106856.
    PubMed    


  574. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
    Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
    Oral Oncol. 2024;154:106855.
    PubMed     Abstract available


  575. PEZZULLA D, Re A, Ferro M, Cilla S, et al
    Lower cranial nerve palsy after hypofractionated radiotherapy in a laryngeal cancer patient: A letter to the editor.
    Oral Oncol. 2024;154:106837.
    PubMed    


  576. ALVES DA MOTA SANTANA L, Gois Floresta L, Maciel Alves EV, Ribeiro Couto G, et al
    Reply to: Comment on "Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes".
    Oral Oncol. 2024;154:106840.
    PubMed    


  577. HE S, Yu H, He L, Liu M, et al
    Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.
    Oral Oncol. 2024;154:106827.
    PubMed     Abstract available


  578. VAZQUEZ FL, Coracin FL, Arantes KLBF, Ferigatto JL, et al
    An oral cancer screening program in Brazil: Analysis of seven years of outcome after its implementation in the suburban cities of Sao Paulo.
    Oral Oncol. 2024;154:106826.
    PubMed     Abstract available


  579. DE FELICE F, Guerrero Urbano T
    Lower-neck sparing in patients with uninvolved neck nasopharyngeal carcinoma: Unquestioned benefit?
    Oral Oncol. 2024;154:106836.
    PubMed    


  580. HAN N, Zhou D, Ruan M, Yan M, et al
    Corrigendum to "Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer" [Oral Oncol. 145 (2023) 106524].
    Oral Oncol. 2024 May 9:106831. doi: 10.1016/j.oraloncology.2024.106831.
    PubMed    


  581. INVERNIZZI C, Da Silva Ribeiro Mota A, Barbe C, Bouazzi L, et al
    Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;153:106833.
    PubMed     Abstract available


  582. PADERNO A, Petrelli F, Lorini L, Capriotti V, et al
    The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;153:106799.
    PubMed     Abstract available


  583. LIU Y, Zuo ZC, Zeng XY, Ma J, et al
    Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.
    Oral Oncol. 2024;153:106834.
    PubMed     Abstract available


  584. XU Y, Xu T, Yao Q, Chen J, et al
    Individualized radiology screening for newly diagnosed nasopharyngeal carcinoma.
    Oral Oncol. 2024;153:106828.
    PubMed     Abstract available


  585. ALMANGUSH A, Makitie AA, Leivo I
    Assessment of tumor-infiltrating lymphocytes in head and neck cancer: Clinical scenarios.
    Oral Oncol. 2024;153:106829.
    PubMed    


  586. DAS R, Misra SR
    Author's reply to comment on "awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;153:106832.
    PubMed    


  587. DHARMALINGAM JOTHINATHAN MK
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106811.
    PubMed    


  588. POOJARI M, Madabhavi I, Desai S
    Extraskeletal Ewing's sarcoma of supraglottis: A rare case report.
    Oral Oncol. 2024;152:106789.
    PubMed     Abstract available


  589. MELDGAARD JUSTESEN M, Kronberg Jakobsen K, Fenger Carlander AL, Hjordt Holm Larsen M, et al
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106783.
    PubMed     Abstract available


    April 2024
  590. TONSBEEK AM, Hundepool CA, Roubos J, Rijken B, et al
    Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module.
    Oral Oncol. 2024;153:106813.
    PubMed     Abstract available


  591. MICHIKAWA C, Gleber-Netto FO, Pickering CR, Rao X, et al
    Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer.
    Oral Oncol. 2024;153:106729.
    PubMed     Abstract available


  592. FANG Q, Yuan J, Zhang X, Dai L, et al
    Oncologic and functional results between sentinel lymph node biopsy and elective neck dissection in cT1/2N0 maxillary squamous cell carcinoma.
    Oral Oncol. 2024;152:106810.
    PubMed     Abstract available


  593. YEO BSY, Lee RS, Lim NE, Tan E, et al
    Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
    Oral Oncol. 2024;152:106786.
    PubMed     Abstract available


  594. LI Y, Zhou Y, Zhao C, Liu L, et al
    The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis.
    Oral Oncol. 2024;152:106798.
    PubMed     Abstract available


  595. RAMASAMY P, Sekaran S, Ganapathy D
    Oral cancer burden in tribal populations residing in India.
    Oral Oncol. 2024;152:106801.
    PubMed    


  596. SEKAR D
    Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106800.
    PubMed    


  597. SARAVANAN M
    Comment on "Nanomedicine, an emerging therapeutic strategy for oral cancer therapy".
    Oral Oncol. 2024;152:106806.
    PubMed    


  598. RICARDO ELIAS DE MELO P, Agra Monteiro M, Henrique Rocha Aragao H, Vitoria de Araujo Lopes N, et al
    Comment on "Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;152:106802.
    PubMed    


  599. SMITH JD, Heft-Neal ME, Rosko AJ, Chepeha DB, et al
    Upfront neck dissection to guide single-modality therapy for early stage supraglottic squamous cell carcinoma.
    Oral Oncol. 2024;152:106803.
    PubMed    


  600. KONO M, Saito S, Rokugo M, Egloff AM, et al
    Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Oral Oncol. 2024;152:106795.
    PubMed     Abstract available


  601. SEGNA E, Civita F, Denaro N, Beltramini GA, et al
    Cavernous sinus metastasis in head and neck cancer: Focus on oral squamous cell cancer.
    Oral Oncol. 2024;152:106784.
    PubMed     Abstract available


  602. SIVAPERUMAL P, Ganapathy D, Kamala K
    Revolutionizing oral cancer treatment: Harnessing the potential of adaptive CARneg T cell therapy.
    Oral Oncol. 2024;152:106794.
    PubMed    


  603. RAJAKUMAR HK, Coimbatore Sathyabal V, Vivekanandam A, Nasrin Jabarulla K, et al
    Evaluation of nuclear morphometry in exfoliative cytology of buccal mucosa in patients with high risk of oral cancer.
    Oral Oncol. 2024;152:106793.
    PubMed     Abstract available


  604. SARAVANAN M
    Comment on "The microbiome and oral cancer: More questions than answers".
    Oral Oncol. 2024;152:106792.
    PubMed    


  605. ARAGAO HHR, Monteiro MA, Lopes NVA, Cunha JLS, et al
    Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
    Oral Oncol. 2024;152:106788.
    PubMed    


  606. DAS R, Misra SR, Nayak A
    Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?
    Oral Oncol. 2024;152:106790.
    PubMed    


  607. XIAO X, Shi Z, Song Z
    Comment on circulatory mitochondrial DNA as a novel biomarker for head and neck cancers.
    Oral Oncol. 2024;152:106785.
    PubMed    


  608. GASNE C, Atallah S, Dauzier E, Thariat J, et al
    Twelve years after: The french national network on rare head and neck tumours (REFCOR).
    Oral Oncol. 2024;151:106762.
    PubMed     Abstract available


  609. MALI SB
    Role of telemedicine in head neck cancer.
    Oral Oncol. 2024;151:106746.
    PubMed     Abstract available


  610. MIRIMOGHADDAM M, Bohlouli B, Lai H, Viegas S, et al
    Trends and predictors of unplanned hospitalization among oral and oropharyngeal cancer patients; an 8-year population-based study.
    Oral Oncol. 2024;151:106742.
    PubMed     Abstract available


    March 2024
  611. MEGAHED R, Prabhu AV, Mack DP, Gholami S, et al
    Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
    Oral Oncol. 2024;152:106778.
    PubMed     Abstract available


  612. LORINI L, Gili R, Salvestrini V, Morelli I, et al
    De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
    Oral Oncol. 2024;152:106768.
    PubMed     Abstract available


  613. XIROU V, Moutafi M, Bai Y, Nwe Aung T, et al
    An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;152:106750.
    PubMed     Abstract available


  614. HONG RL, Yen CJ, Lien MY, Cheng R, et al
    Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106760.
    PubMed     Abstract available


  615. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group.
    Oral Oncol. 2024;152:106744.
    PubMed     Abstract available


  616. TOYA R, Fukugawa Y, Saito T, Matsuyama T, et al
    Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
    Oral Oncol. 2024;151:106752.
    PubMed     Abstract available


  617. RUIZ-TORRES DA, Naegele S, Podury A, Wirth L, et al
    Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
    Oral Oncol. 2024;151:106761.
    PubMed     Abstract available


  618. SIMON L, Paly J, Park E, Samuels-Kalow M, et al
    Medicare dental coverage for patients with head and neck cancer: An opportunity in need of advocates.
    Oral Oncol. 2024 Mar 15:106754. doi: 10.1016/j.oraloncology.2024.106754.
    PubMed    


  619. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    Comment on "advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with Teledentistry for Better Patient Outcomes".
    Oral Oncol. 2024;151:106758.
    PubMed    


  620. RAJANATHADURAI J, Sindya J, Madar IH, Perumal E, et al
    Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
    Oral Oncol. 2024;151:106748.
    PubMed    


  621. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
    Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Oral Oncol. 2024;151:106749.
    PubMed     Abstract available


  622. FERRARO T, Pershad AR, Arora S, Lee E, et al
    The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2024;151:106743.
    PubMed     Abstract available


  623. KIM DH, Lim ST, Kim HR, Kang EJ, et al
    Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Oral Oncol. 2024;151:106739.
    PubMed     Abstract available


  624. SANTANA LADM, Floresta LG, Alves EVM, Melo LMR, et al
    Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes.
    Oral Oncol. 2024;151:106741.
    PubMed    


  625. CHEN K, Shi M, Mo S, Liu T, et al
    Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.
    Oral Oncol. 2024;151:106738.
    PubMed     Abstract available


  626. DING C, Dai DY, Luo ZK, Wang GY, et al
    Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
    Oral Oncol. 2024;151:106725.
    PubMed     Abstract available


  627. LU X, Zhang JL, Zhai X, Liu Q, et al
    A case report on a nasal and oral cavity involving large solitary fibrous tumor and comprehensive review of case literature.
    Oral Oncol. 2024;150:106715.
    PubMed     Abstract available


  628. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    PubMed     Abstract available


    February 2024
  629. VAN SCHAIK JE, van der Vegt B, Slagter-Menkema L, van der Laan BFAM, et al
    Identification of new head and neck squamous cell carcinoma molecular imaging targets.
    Oral Oncol. 2024;151:106736.
    PubMed     Abstract available


  630. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
    Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
    Oral Oncol. 2024;151:106703.
    PubMed     Abstract available


  631. AHMED AA, Sborchia M, Bye H, Roman-Escorza M, et al
    Mutation detection in saliva from oral cancer patients.
    Oral Oncol. 2024;151:106717.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum